MD, PhD, FMedSci, FRSB, FRCP, FRCPEd.

The current issues of ‘homeopathy 4 everyone’ (April 2016) carries several articles on homeoprophylaxis, the use of homeopathic remedies for the prevention of mostly infectious diseases promoted by homeopathy as a safe and effective alternative to immunizations. They are worth reading – but watch your blood pressure! Here I will give you a flavour by citing from one of these articles:

“…As I have been teaching about Homeoprophylaxis (“HP”) throughout the United States and in Europe, some things have become unmistakably clear.  One is the ever increasing desire of people to know that there is a nontoxic alternative when it comes to disease prevention.  Another is a profound misunderstanding or, perhaps better said, a lack of education among many regarding HP…

The effectiveness of HP is being shown fairly consistently to be about 90%1, which is comparable to any vaccine.  With this in mind, too, those who utilize homeoprophylaxis work to help their clients understand fundamentally that disease is generally not to be feared—that disease-causing pathogens are a necessary part of our environment and that the body generally becomes healthier once it has been exposed to a disease and has worked its way through it…

My passion regarding spreading the word and helping people learn about homeoprophylaxis led to my becoming the co-founder/director of the first international conference of its type in the world—Homeoprophylaxis: A Worldwide Choice, which took place in Dallas, Texas, USA in October, 2015.  Isaac Golden was our keynote speaker…

Frequently seen is the protocol Isaac Golden utilizes. This is a once monthly method, where one single remedy/nosode is introduced at potency.  If following, for example, a pediatric regimen that lists several nosodes, it will be the next month that either a larger dose of that same nosode is taken, or the next nosode is introduced.  For pediatric HP, this is cycled through until all nosodes in the protocol are taken, the higher potency being started after the lower potency is completed. A booklet is provided to the clientele to keep track of these…

Ultimately, homeoprophylaxis has been in use since the days of Hahnemann.  What is apparent when one considers the entire picture, noting the meticulous studies that have been and are yet being done as well as the current increasing demand of people worldwide— perhaps especially parents— for a nontoxic alternative for disease prevention, it truly makes sense to be promoting  homeoprophylaxis.  Our children are the most vulnerable in our society and deserve our utmost attention and concern.  Not every practitioner needs to utilize HP.  However, because there are many who do, support of this should be encouraged.  It is an alternative people deserve to know about so that they can make an educated choice, and health for our society, especially our children, can be promoted.”

END OF QUOTE

By now, you are probably wondering who wrote this article. It was Cathy Lemmon, BA, C.HP, D.Psc,  Co-Founder/Director of Homeoprophylaxis: A Worldwide Choice for Disease Prevention, she is also working on future conferences for the promotion of HP. She has studied HP with Isaac Golden of Australia and Ravi Roy and Carola Lage-Roy of Germany. She also has certificates in homeopathic treatment of vaccine injury as well as, through the ARHF in the Netherlands, treatment of epidemics and trauma. She completed studies at the School of Homeopathy and is completing specialized homeopathic studies through Gesundes Bewußtsein in Germany as well as post-graduate work in homeopathy through the College of Practical Homeopathy in London.

With all these ‘qualifications’, she has obviously escaped any education in real science and evidence-based medicine; if not she would know that her views are not just wrong but also dangerous. To Be clear:

  • Homeoprophylaxis is not biologically plausible.
  • There is no evidence that it works.
  • The concept misleads people to think that conventional immunizations are superfluous.
  • This has the potential to kill thousands.

94 Responses to Understanding homeoprophylaxis: it is dangerous nonsense!!!

  • If only Isaac Golden’s claims could be assessed by a court or something ans we could find out if they have any merit.

    Oh, look! https://luckylosing.com/tag/isaac-golden/

  • why are they not fined for advertising and promoting this fake vaccine to replace scientifically and clinically proven vaccines?

    • I’m not saying that this alternative is the best or if is safe, BUT pharmaceutical companies and health care authorities, not only should be fined, but taken to court, BECAUSE, the current vaccines, have not been “clinically” proven safe either, in fact, there are thousands of scientific studies, that demonstrate that the current vaccines are not safe.

      • Yes! And the studies that are done are funded by the pharmaceutical companies themselves so where can we find REAL information on this?

        • Maybe you think the public should foot the bill for clinical trials?

          • The NIH used to be the source of clinical trials in USA until
            the Reagan era when the political powers decided those who gain the most from these studies should fund them. Why should those who gain the most provide any unbiased, pure scientific information when much of it could result in their gains being reduced or eliminated. No brainer to me that those with the least to gain should be the source of this information.

          • I can’t comment on the NIH funding medicine trials in the past, but they certainly do still fund trials of quackery – they have spent billions on it with virtually nothing to show for it but negative trials.

            But good luck trying to get the public to pay for trials directly – they already do indirectly, of course, through the prices pharmaceutical companies charge for their products.

      • Vaccines are extensively studied and their safety tested by many other than pharmaceutical manufacturers. As one example, governmental institutions in the Nordic countries carry out extensive surveillance, testing and research which is totally independent from manufacturers and other interests.
        This information is rather easy to assemble.
        The false information and blatant lies going on about vaccine research and we see examples of here in this discussion is abhorring and destructive.

        • Give me an example of one double blinded placebo studie done on vaccines! Oh righ… they don’t excist!

          Because the fact is that when they tested vaccines they didnt use a true placebo but rather another vaccine or an aluminum adjuvent as the placebo, the reason was that it would be unethical. So this is not really acceptable atleast for me as an safety study… what I want as a citizen of the world is that they atleast test the vaccinated with the unvaccinated groups in every single vaccine!

          Am I wrong?

          Heres an interesting video about homeo prophylaxis, and theis person in the video explanes why they havent excepted the safety studies that actually do excist!

          People do your research, don’t blindly believe what people say!

          • “Am I wrong? ”
            Yes!

          • Edzart, specifically what part is Angel wrong about? Is there a double blind placebo study on vaccines?

          • @Angel and Kandace Reed

            Here are the details of the 258 professional publications listed on Medline with the words ‘vaccine’ and ‘placebo-controlled’ in the title. If that’s not enough for you, there are 1461 references with the same words as keywords.

            [The list is apparently too long to post in a single comment, so I’ll split it into three parts. Enjoy your reading!]

            1. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
            Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y.
            Vaccine. 2019 Feb 20.
            [Journal Article]
            UI: 30797638
            2. Local and Systemic Immunity Against RSV Induced by a Novel Intranasal Vaccine: A Randomised, Double- Blind, Placebo-Controlled Trial.
            Ascough S; Vlachantoni I; Kalyan M; Haijema BJ; Wallin-Weber S; Dijkstra-Tiekstra M; Ahmed MS; van Roosmalen M; Grimaldi R; Zhang Q; Leenhouts K; Openshaw PJ; Chiu C.
            American Journal of Respiratory & Critical Care Medicine. 2019 Feb 12.
            [Journal Article]
            UI: 30753101
            3. Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
            Hao B; Chen Z; Zeng G; Huang L; Luan C; Xie Z; Chen J; Bao M; Tian X; Xu B; Wang Y; Wu J; Xia S; Yuan L; Huang J.
            Clinical Microbiology & Infection. 2019 Jan 04.
            [Journal Article]
            UI: 30616012
            4. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.
            Woods CW; Sanchez AM; Swamy GK; McClain MT; Harrington L; Freeman D; Poore EA; Slifka DK; Poer DeRaad DE; Amanna IJ; Slifka MK; Cai S; Shahamatdar V; Wierzbicki MR; Amegashie C; Walter EB.
            Vaccine. 2019 Jan 18.
            [Journal Article]
            UI: 30661836
            5. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
            Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinon-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I; GQM05 Study Group.
            Vaccine. 2018 Dec 14.
            [Journal Article]
            UI: 30558818
            6. Immunogenicity and viral shedding of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled trial among pre-school aged children in urban Bangladesh.
            Lewis KDC; Ortiz JR; Rahman MZ; Levine MZ; Rudenko L; Wright PF; Katz JM; Dally L; Rahman M; Isakova-Sivak I; Ilyushina NA; Matyushenko V; Fry AM; Lindstrom ST; Bresee JS; Brooks WA; Neuzil KM.
            Clinical Infectious Diseases. 2018 Nov 27.
            [Journal Article]
            UI: 30481272
            7. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
            Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A.
            Vaccine. 2018 Nov 22.
            [Journal Article]
            UI: 30473185
            8. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.
            Wei L; Xie X; Liu J; Zhao Y; Chen W; Zhao C; Wang S; Liao X; Shou Q; Qiu Y; Qiao Y; Saah AJ.
            Vaccine. 2018 Aug 16.
            [Journal Article]
            UI: 30122646
            9. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.
            Kim L; Liebowitz D; Lin K; Kasparek K; Pasetti MF; Garg SJ; Gottlieb K; Trager G; Tucker SN.
            Jci Insight. 3(13), 2018 Jul 12.
            [Journal Article]
            UI: 29997294
            10. A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single >=2×108 colony forming units [cfu] standard-dose versus a >=2×109 cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open label immunologic comparator.
            Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traore A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM.
            Clinical & Vaccine Immunology: CVI. 2017 Oct 11.
            [Journal Article]
            UI: 29021299
            11. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
            Schmitz-Winnenthal FH; Hohmann N; Niethammer AG; Friedrich T; Lubenau H; Springer M; Breiner KM; Mikus G; Weitz J; Ulrich A; Buechler MW; Pianka F; Klaiber U; Diener M; Leowardi C; Schimmack S; Sisic L; Keller AV; Koc R; Springfeld C; Knebel P; Schmidt T; Ge Y; Bucur M; Stamova S; Podola L; Haefeli WE; Grenacher L; Beckhove P.
            Oncoimmunology. 4(4):e1001217, 2015 Apr.
            [Journal Article]
            UI: 26137397
            12. Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial.
            Goncalves-Mendes N; Talvas J; Duale C; Guttmann A; Corbin V; Marceau G; Sapin V; Brachet P; Evrard B; Laurichesse H; Vasson MP.
            Frontiers in Immunology. 10:65, 2019.
            [Journal Article]
            UI: 30800121
            13. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
            Blauvelt A; Simpson EL; Tyring SK; Purcell LA; Shumel B; Petro CD; Akinlade B; Gadkari A; Eckert L; Graham NMH; Pirozzi G; Evans R.
            Journal of the American Academy of Dermatology. 80(1):158-167.e1, 2019 Jan.
            [Journal Article]
            UI: 30092324
            14. Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.
            Inoue M; Ogawa T; Tamura H; Hagiwara Y; Saito Y; Abbanat D; van den Dobbelsteen G; Hermans P; Thoelen S; Poolman J; Ibarra de Palacios P.
            Human vaccines & Immunotherapeutics. 14(9):2150-2157, 2018.
            [Journal Article. Research Support, Non-U.S. Gov’t]
            UI: 29771596
            15. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90months of follow-up.
            Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y.
            Vaccine. 37(6):889-897, 2019 Feb 04.
            [Journal Article]
            UI: 30638797
            16. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
            Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M; H56-035 Trial Group.
            American Journal of Respiratory & Critical Care Medicine. 199(2):220-231, 2019 Jan 15.
            [Journal Article]
            UI: 30092143
            17. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
            Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K.
            Lancet. 392(10165):2718-2727, 2019 12 22.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 30409443
            18. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
            Saez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D.
            The Lancet Infectious Diseases. 18(2):162-170, 2018 02.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 29122463
            19. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.
            Olotu A; Urbano V; Hamad A; Eka M; Chemba M; Nyakarungu E; Raso J; Eburi E; Mandumbi DO; Hergott D; Maas CD; Ayekaba MO; Milang DN; Rivas MR; Schindler T; Embon OM; Ruben AJ; Saverino E; Abebe Y; Kc N; James ER; Murshedkar T; Manoj A; Chakravarty S; Li M; Adams M; Schwabe C; Segura JL; Daubenberger C; Tanner M; Richie TL; Billingsley PF; Lee Sim BK; Abdulla S; Hoffman SL.
            American Journal of Tropical Medicine & Hygiene. 98(1):308-318, 2018 01.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 29141739
            20. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
            Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H.
            Lancet. 392(10143):232-243, 2018 07 21.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 30047376
            21. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial.
            Brooks WA; Zaman K; Lewis KD; Ortiz JR; Goswami D; Feser J; Sharmeen AT; Nahar K; Rahman M; Rahman MZ; Barin B; Yunus M; Fry AM; Bresee J; Azim T; Neuzil KM.
            The Lancet Global Health. 4(12):e946-e954, 2016 12.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 27746226
            22. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
            Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Kulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B.
            Journal of Medical Virology. 90(1):41-49, 2018 01.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 28842994
            23. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
            Niethammer AG; Lubenau H; Mikus G; Knebel P; Hohmann N; Leowardi C; Beckhove P; Akhisaroglu M; Ge Y; Springer M; Grenacher L; Buchler MW; Koch M; Weitz J; Haefeli WE; Schmitz-Winnenthal FH.
            BMC Cancer. 12:361, 2012 Aug 20.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22906006
            24. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
            Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA; V920-012 Study Team.
            Journal of Infectious Diseases. 215(12):1789-1798, 2017 06 15.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28549145
            25. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
            Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Zak P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A; V212 Protocol 001 Trial Team.
            Lancet. 391(10135):2116-2127, 2018 05 26.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 29856344
            26. Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial.
            Coldiron ME; Guindo O; Makarimi R; Soumana I; Matar Seck A; Garba S; Macher E; Isanaka S; Grais RF.
            Vaccine. 36(25):3674-3680, 2018 06 14.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 29752026
            27. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
            Overton ET; Lawrence SJ; Wagner E; Nopora K; Rosch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P.
            PLoS ONE [Electronic Resource]. 13(4):e0195897, 2018.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 29652929
            28. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
            Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M; TBVPX-114 study team.
            The Lancet Respiratory Medicine. 6(4):287-298, 2018 04.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 29595510
            29. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
            Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K.
            Transplant Infectious Disease. 20(3):e12874, 2018 Jun.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 29512282
            30. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
            Modjarrad K; Lin L; George SL; Stephenson KE; Eckels KH; De La Barrera RA; Jarman RG; Sondergaard E; Tennant J; Ansel JL; Mills K; Koren M; Robb ML; Barrett J; Thompson J; Kosel AE; Dawson P; Hale A; Tan CS; Walsh SR; Meyer KE; Brien J; Crowell TA; Blazevic A; Mosby K; Larocca RA; Abbink P; Boyd M; Bricault CA; Seaman MS; Basil A; Walsh M; Tonwe V; Hoft DF; Thomas SJ; Barouch DH; Michael NL.
            Lancet. 391(10120):563-571, 2018 02 10.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 29217375
            31. The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: A randomized, factorial design, placebo-controlled study among Indian infants.
            Lazarus RP; John J; Shanmugasundaram E; Rajan AK; Thiagarajan S; Giri S; Babji S; Sarkar R; Kaliappan PS; Venugopal S; Praharaj I; Raman U; Paranjpe M; Grassly NC; Parker EPK; Parashar UD; Tate JE; Fleming JA; Steele AD; Muliyil J; Abraham AM; Kang G.
            Vaccine. 36(2):273-279, 2018 01 04.
            [Journal Article. Randomized Controlled Trial]
            UI: 28874323
            32. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
            Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z.
            Clinical Infectious Diseases. 65(7):1174-1182, 2017 Oct 01.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 29126292
            33. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
            Mo Z; Mo Y; Li M; Tao J; Yang X; Kong J; Wei D; Fu B; Liao X; Chu J; Qiu Y; Hille DA; Nelson M; Kaplan SS.
            Vaccine. 35(43):5897-5904, 2017 10 13.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28935470
            34. Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
            Buchbinder SP; Grunenberg NA; Sanchez BJ; Seaton KE; Ferrari G; Moody MA; Frahm N; Montefiori DC; Hay CM; Goepfert PA; Baden LR; Robinson HL; Yu X; Gilbert PB; McElrath MJ; Huang Y; Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.
            PLoS ONE [Electronic Resource]. 12(7):e0179597, 2017.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 28727817
            35. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
            Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR; TIV-MNP 2015 Study Group.
            Lancet. 390(10095):649-658, 2017 08 12.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 28666680
            36. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
            Heppner DG Jr; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; V920-004 study team.
            The Lancet Infectious Diseases. 17(8):854-866, 2017 08.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, U.S. Gov’t, P.H.S.]
            UI: 28606591
            37. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
            August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF.
            Vaccine. 35(30):3749-3759, 2017 06 27.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28579233
            38. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
            Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP.
            The Lancet Infectious Diseases. 17(8):833-842, 2017 08.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28533093
            39. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
            Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S.
            The Lancet Infectious Diseases. 17(8):843-853, 2017 08.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28483414
            40. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
            van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E.
            BMC Infectious Diseases. 17(1):241, 2017 04 04.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 28376743
            41. Safety and immunogenicity of one versus two doses of Takeda’s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
            Saez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D.
            The Lancet Infectious Diseases. 17(6):615-625, 2017 06.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28365225
            42. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.
            Huttner A; Hatz C; van den Dobbelsteen G; Abbanat D; Hornacek A; Frolich R; Dreyer AM; Martin P; Davies T; Fae K; van den Nieuwenhof I; Thoelen S; de Valliere S; Kuhn A; Bernasconi E; Viereck V; Kavvadias T; Kling K; Ryu G; Hulder T; Groger S; Scheiner D; Alaimo C; Harbarth S; Poolman J; Fonck VG.
            The Lancet Infectious Diseases. 17(5):528-537, 2017 05.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28238601
            43. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.
            Rello J; Krenn CG; Locker G; Pilger E; Madl C; Balica L; Dugernier T; Laterre PF; Spapen H; Depuydt P; Vincent JL; Bogar L; Szabo Z; Volgyes B; Manez R; Cakar N; Ramazanoglu A; Topeli A; Mastruzzo MA; Jasovich A; Remolif CG; Del Carmen Soria L; Andresen Hernandez MA; Ruiz Balart C; Kremer I; Molnar Z; von Sonnenburg F; Lyons A; Joannidis M; Burgmann H; Welte T; Klingler A; Hochreiter R; Westritschnig K.
            Critical Care (London, England). 21(1):22, 2017 02 04.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 28159015
            44. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.
            Izumi Y; Akazawa M; Akeda Y; Tohma S; Hirano F; Ideguchi H; Matsumura R; Miyamura T; Mori S; Fukui T; Iwanaga N; Jiuchi Y; Kozuru H; Tsutani H; Saisyo K; Sugiyama T; Suenaga Y; Okada Y; Katayama M; Ichikawa K; Furukawa H; Kawakami K; Oishi K; Migita K.
            Arthritis Research & Therapy. 19(1):15, 2017 01 25.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28122642
            45. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
            Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W.
            The Lancet Global Health. 5(3):e324-e334, 2017 03.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 28017642
            46. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
            Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W.
            Lancet. 389(10069):621-628, 2017 02 11.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 28017399
            47. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
            Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M.
            Lancet Neurology. 16(2):123-134, 2017 Feb.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 27955995
            48. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.
            Collett MS; Hincks JR; Benschop K; Duizer E; van der Avoort H; Rhoden E; Liu H; Oberste MS; McKinlay MA; Hartford M.
            Journal of Infectious Diseases. 215(3):335-343, 2017 Feb 01.
            [Journal Article. Randomized Controlled Trial]
            UI: 27932608
            49. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
            Frenck RW Jr; Creech CB; Sheldon EA; Seiden DJ; Kankam MK; Baber J; Zito E; Hubler R; Eiden J; Severs JM; Sebastian S; Nanra J; Jansen KU; Gruber WC; Anderson AS; Girgenti D.
            Vaccine. 35(2):375-384, 2017 01 05.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 27916408
            50. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.
            Malfertheiner P; Selgrad M; Wex T; Romi B; Borgogni E; Spensieri F; Zedda L; Ruggiero P; Pancotto L; Censini S; Palla E; Kanesa-Thasan N; Scharschmidt B; Rappuoli R; Graham DY; Schiavetti F; Del Giudice G.
            The Lancet. Gastroenterology & Hepatology. 3(10):698-707, 2018 Oct.
            [Journal Article]
            UI: 30042064
            51. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.
            Van Wagoner N; Fife K; Leone PA; Bernstein DI; Warren T; Panther L; Novak RM; Beigi R; Kriesel J; Tyring S; Koltun W; Lucksinger G; Morris A; Zhang B; McNeil LK; Tasker S; Hetherington S; Wald A.
            Journal of Infectious Diseases. 218(12):1890-1899, 2018 Nov 05.
            [Journal Article]
            UI: 29982727
            52. Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial.
            Awal G; Kaur S.
            The Journal of Clinical & Aesthetic Dermatology. 11(5):15-20, 2018 May.
            [Journal Article]
            UI: 29785233
            53. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.
            Edwards JE Jr; Schwartz MM; Schmidt CS; Sobel JD; Nyirjesy P; Schodel F; Marchus E; Lizakowski M; DeMontigny EA; Hoeg J; Holmberg T; Cooke MT; Hoover K; Edwards L; Jacobs M; Sussman S; Augenbraun M; Drusano M; Yeaman MR; Ibrahim AS; Filler SG; Hennessey JP Jr.
            Clinical Infectious Diseases. 66(12):1928-1936, 2018 Jun 01.
            [Journal Article]
            UI: 29697768
            54. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298.
            Wilkin TJ; Chen H; Cespedes MS; Leon-Cruz JT; Godfrey C; Chiao EY; Bastow B; Webster-Cyriaque J; Feng Q; Dragavon J; Coombs RW; Presti RM; Saah A; Cranston RD.
            Clinical Infectious Diseases. 67(9):1339-1346, 2018 Oct 15.
            [Journal Article]
            UI: 29659751
            55. Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial.
            Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Perez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleon I; San-Jose I; Munuera J; Rodriguez-Gomez O; Abdelnour C; Lafuente A; Buendia M; Boada M; Tarraga L; Ruiz A; Sarasa M.
            Alzheimer’s Research & Therapy. 10(1):12, 2018 Jan 29.
            [Journal Article]
            UI: 29378651
            56. Erratum to “Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults” [Vaccine 34 (2016) 3156-3163].
            Leroux-Roels G; Van Damme P; Haazen W; Shakib S; Caubet M; Aris E; Devaster JM; Peeters M.
            Vaccine. 35(42):5729-5730, 2017 10 09.
            [Journal Article. Published Erratum]
            UI: 28882439
            57. The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants.
            Grassly NC; Praharaj I; Babji S; Kaliappan SP; Giri S; Venugopal S; Parker EP; Abraham A; Muliyil J; Doss S; Raman U; Liu J; Peter JV; Paranjape M; Jeyapaul S; Balakumar S; Ravikumar J; Srinivasan R; Bahl S; Iturriza-Gomara M; Uhlig HH; Houpt ER; John J; Kang G.
            The Lancet Infectious Diseases. 16(8):905-14, 2016 08.
            [Journal Article. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 27156189
            58. Correction: Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.
            PLOS Neglected Tropical Diseases Staff.
            PLoS Neglected Tropical Diseases [electronic resource]. 9(6):e0003891, 2015 Jun.
            [Published Erratum]
            UI: 26107633
            [Erratum for: PLoS Negl Trop Dis. 2015 Jun;9(6):e0003768; PMID: 26053679 [https://www.ncbi.nlm.nih.gov/pub…- opens in a new window]]
            PLOS Neglected Tropical Diseases Staff.
            59. Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.
            Allen KB; Fowler VG Jr; Gammie JS; Hartzel JS; Onorato MT; DiNubile MJ; Sobanjo-Ter Meulen A.
            Open Forum Infectious Diseases. 1(2):ofu071, 2014 Sep.
            [Journal Article]
            UI: 25734141
            60. Granulocyte colony stimulating factor adjuvant role on the immunological response to hepatitis B vaccine in patients with cirrhosis: a double blind randomized placebo controlled trial.
            Lankarani KB; Talebzadeh M; Eshraghian A; Malek-Hosseini SA.
            Hepatitis Monthly. 14(5):e15447, 2014 May.
            [Journal Article]
            UI: 24910704
            61. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.
            Victor JC; Lewis KD; Diallo A; Niang MN; Diarra B; Dia N; Ortiz JR; Widdowson MA; Feser J; Hoagland R; Emery SL; Lafond KE; Neuzil KM.
            The Lancet Global Health. 4(12):e955-e965, 2016 12.
            [Journal Article. Randomized Controlled Trial. Research Support, U.S. Gov’t, P.H.S.. Research Support, Non-U.S. Gov’t]
            UI: 27746224
            62. Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.
            Koram KA; Adu B; Ocran J; Karikari YS; Adu-Amankwah S; Ntiri M; Abuaku B; Dodoo D; Gyan B; Kronmann KC; Nkrumah F.
            PLoS ONE [Electronic Resource]. 11(9):e0163066, 2016.
            [Journal Article. Randomized Controlled Trial]
            UI: 27644034
            63. Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial.
            Mcbride WJH; Abhayaratna WP; Barr I; Booy R; Carapetis J; Carson S; De Looze F; Ellis-Pegler R; Heron L; Karrasch J; Marshall H; Mcvernon J; Nolan T; Rawlinson W; Reid J; Richmond P; Shakib S; Basser RL; Hartel GF; Lai MH; Rockman S; Greenberg ME.
            Vaccine. 34(41):4991-4997, 2016 09 22.
            [Clinical Trial, Phase IV. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 27595443
            64. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam.
            Phan TL; Ho VT; Vu MH; Nguyen TN; Duong HT; Holt R; Wahid R; Donnelly J; Flores J.
            Vaccine. 34(45):5449-5456, 2016 10 26.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 27591953
            65. Effects of typhoid vaccine on inflammation and sleep in healthy participants: a double-blind, placebo-controlled, crossover study.
            Sharpley AL; Cooper CM; Williams C; Godlewska BR; Cowen PJ.
            Psychopharmacology. 233(18):3429-35, 2016 09.
            [Journal Article. Randomized Controlled Trial]
            UI: 27503474
            66. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects.
            Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Roesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P.
            PLoS ONE [Electronic Resource]. 11(6):e0157335, 2016.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 27327616
            67. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults.
            Leroux-Roels G; Van Damme P; Haazen W; Shakib S; Caubet M; Aris E; Devaster JM; Peeters M.
            Vaccine. 34(27):3156-3163, 2016 06 08.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 27133877
            68. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.
            Sheldon E; Kitchin N; Peng Y; Eiden J; Gruber W; Johnson E; Jansen KU; Pride MW; Pedneault L.
            Vaccine. 34(18):2082-91, 2016 Apr 19.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26993331
            69. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
            De Santis O; Audran R; Pothin E; Warpelin-Decrausaz L; Vallotton L; Wuerzner G; Cochet C; Estoppey D; Steiner-Monard V; Lonchampt S; Thierry AC; Mayor C; Bailer RT; Mbaya OT; Zhou Y; Ploquin A; Sullivan NJ; Graham BS; Roman F; De Ryck I; Ballou WR; Kieny MP; Moorthy V; Spertini F; Genton B.
            The Lancet Infectious Diseases. 16(3):311-20, 2016 Mar.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26725450
            70. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
            Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT.
            Journal of Infectious Diseases. 213(10):1562-72, 2016 May 15.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26704612
            71. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
            Rudenko L; Isakova-Sivak I; Naykhin A; Kiseleva I; Stukova M; Erofeeva M; Korenkov D; Matyushenko V; Sparrow E; Kieny MP.
            The Lancet Infectious Diseases. 16(3):303-10, 2016 Mar.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26673391
            72. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
            Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T.
            Diabetic Medicine. 33(8):1094-101, 2016 08.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26605507
            73. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
            Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM.
            The Lancet Infectious Diseases. 16(1):31-42, 2016 Jan.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 26546548
            74. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
            Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J.
            Human vaccines & Immunotherapeutics. 12(2):512-8, 2016.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26291554
            75. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
            Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML.
            Lancet. 386(10008):2078-2088, 2015 Nov 21.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26386540
            76. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
            Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD; RV3 Rotavirus Vaccine Program.
            The Lancet Infectious Diseases. 15(12):1389-97, 2015 Dec.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26318715
            77. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
            Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J; Russian LAIV Trial Study Group.
            Vaccine. 33(39):5110-7, 2015 Sep 22.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26296497
            78. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
            Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C.
            PLoS ONE [Electronic Resource]. 10(8):e0134287, 2015.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26252526
            79. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
            Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krahling V; Kwilas S; Lemaitre B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA; VSV-Ebola Consortium.
            The Lancet Infectious Diseases. 15(10):1156-1166, 2015 Oct.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 26248510
            80. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.
            Zeng M; Mao XH; Li JX; Tong WD; Wang B; Zhang YJ; Guo G; Zhao ZJ; Li L; Wu DL; Lu DS; Tan ZM; Liang HY; Wu C; Li DH; Luo P; Zeng H; Zhang WJ; Zhang JY; Guo BT; Zhu FC; Zou QM.
            Lancet. 386(10002):1457-64, 2015 Oct 10.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26142048
            81. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
            Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A.
            American Journal of Tropical Medicine & Hygiene. 93(3):527-33, 2015 Sep.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26078323
            82. Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.
            Bruckner S; Agnandji ST; Berberich S; Bache E; Fernandes JF; Schweiger B; Massinga Loembe M; Engleitner T; Lell B; Mordmuller B; Adegnika AA; Yazdanbakhsh M; Kremsner PG; Esen M.
            PLoS Neglected Tropical Diseases [electronic resource]. 9(6):e0003768, 2015.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 26053679
            83. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
            Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F.
            PLoS ONE [Electronic Resource]. 10(5):e0125954, 2015.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 25961283
            84. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
            Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M.
            Vaccine. 33(25):2944-54, 2015 Jun 09.
            [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 25936724
            85. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
            Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA.
            Vaccine. 33(29):3415-21, 2015 Jun 26.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25917680
            86. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
            Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W.
            Lancet. 385(9984):2272-9, 2015 Jun 06.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25817373
            87. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
            Ramsauer K; Schwameis M; Firbas C; Mullner M; Putnak RJ; Thomas SJ; Despres P; Tauber E; Jilma B; Tangy F.
            The Lancet Infectious Diseases. 15(5):519-27, 2015 May.
            [Clinical Trial, Phase I. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25739878
            88. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
            Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dieye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H; MVA85A 030 trial investigators.
            The Lancet Respiratory Medicine. 3(3):190-200, 2015 Mar.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25726088
            89. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial.
            Russell KL; Baker CI; Hansen C; Poland GA; Ryan MA; Merrill MM; Gray GC.
            Vaccine. 33(9):1182-7, 2015 Feb 25.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 25579777
            90. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
            Berkowitz EM; Moyle G; Stellbrink HJ; Schurmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC; Zoster-015 HZ/su Study Group.
            Journal of Infectious Diseases. 211(8):1279-87, 2015 Apr 15.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25371534
            91. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
            Kosalaraksa P; Jeanfreau R; Frenette L; Drame M; Madariaga M; Innis BL; Godeaux O; Izurieta P; Vaughn DW.
            Journal of Infectious Diseases. 211(5):801-10, 2015 Mar 01.
            [Clinical Trial, Phase II. Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, P.H.S.]
            UI: 25293368
            92. Safety and immunogenicity of H1/IC31, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
            Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ.
            PLoS ONE [Electronic Resource]. 9(12):e114602, 2014.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25490675
            93. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
            Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM.
            Vaccine. 32(52):7077-84, 2014 Dec 12.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25444830
            94. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.
            Lawrence J; He S; Martin J; Schodel F; Ciarlet M; Murray AV.
            Human vaccines & Immunotherapeutics. 10(8):2247-54, 2014.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25424929
            95. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
            Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT.
            The Lancet Infectious Diseases. 14(9):830-8, 2014 Sep.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 25087476
            96. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
            Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A; CYD14 Study Group.
            Lancet. 384(9951):1358-65, 2014 Oct 11.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 25018116
            97. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India.
            Kanungo S; Sen B; Ramamurthy T; Sur D; Manna B; Pazhani GP; Chowdhury G; Jhunjhunwala P; Nandy RK; Koley H; Bhattacharya MK; Gupta S; Goel G; Dey B; M T; Nair GB; Ghosh A; Mahalanabis D.
            PLoS ONE [Electronic Resource]. 9(7):e99381, 2014.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24983989
            98. Efficacy of the nicotine vaccine 3′-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.
            Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; van Schayck OC.
            Addiction. 109(8):1252-9, 2014 Aug.
            [Journal Article. Randomized Controlled Trial]
            UI: 24894625
            99. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies.
            Basavaraj VH; Sampath G; Hegde NR; Mohan VK; Ella KM.
            Vaccine. 32(35):4592-7, 2014 Jul 31.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 24856782
            100. Incidence of influenza virus infections in children in Hong Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012.
            Cowling BJ; Perera RA; Fang VJ; Chan KH; Wai W; So HC; Chu DK; Wong JY; Shiu EY; Ng S; Ip DK; Peiris JS; Leung GM.
            Clinical Infectious Diseases. 59(4):517-24, 2014 Aug 15.
            [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24825868

          • thanks for doing this; it was on my ‘to do list’ and you saved me the effort.

          • @Angel and Kandace

            Professional publications on placebo-controlled trials of vaccines, part 2.

            101. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.
            Kosten TR; Domingo CB; Shorter D; Orson F; Green C; Somoza E; Sekerka R; Levin FR; Mariani JJ; Stitzer M; Tompkins DA; Rotrosen J; Thakkar V; Smoak B; Kampman K.
            Drug & Alcohol Dependence. 140:42-7, 2014 Jul 01.
            [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 24793366
            102. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
            Alfonso S; Valdes-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernandez M; Viada CE; Mendoza IC; Guerra PP; Garcia E; Ortiz RA; de la Torre AV; Cepeda M; Perez K; Chong E; Hernandez AM; Toledo D; Gonzalez Z; Mazorra Z; Crombet T; Perez R; Vazquez AM; Macias AE.
            Clinical Cancer Research. 20(14):3660-71, 2014 Jul 15.
            [Clinical Trial, Phase II. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24788102
            103. Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults.
            Paul A; Babji S; Sowmyanarayanan TV; Dhingra MS; Ramani S; Kattula D; Kang G.
            Vaccine. 32(25):3094-100, 2014 May 23.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 24704505
            104. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.
            Bhandari N; Rongsen-Chandola T; Bavdekar A; John J; Antony K; Taneja S; Goyal N; Kawade A; Kang G; Rathore SS; Juvekar S; Muliyil J; Arya A; Shaikh H; Abraham V; Vrati S; Proschan M; Kohberger R; Thiry G; Glass R; Greenberg HB; Curlin G; Mohan K; Harshavardhan GV; Prasad S; Rao TS; Boslego J; Bhan MK; India Rotavirus Vaccine Group.
            Lancet. 383(9935):2136-43, 2014 Jun 21.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 24629994
            105. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial.
            Shenyu W; Jingxin L; Zhenglun L; Xiuling L; Qunying M; Fanyue M; Hua W; Yuntao Z; Fan G; Qinghua C; Yuemei H; Xin Y; Huijie G; Fengcai Z.
            Journal of Infectious Diseases. 210(7):1073-82, 2014 Oct 01.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24625805
            106. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.
            Nell AS; D’lom E; Bouic P; Sabate M; Bosser R; Picas J; Amat M; Churchyard G; Cardona PJ.
            PLoS ONE [Electronic Resource]. 9(2):e89612, 2014.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24586912
            107. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.
            Rudenko L; Kiseleva I; Naykhin AN; Erofeeva M; Stukova M; Donina S; Petukhova G; Pisareva M; Krivitskaya V; Grudinin M; Buzitskaya Z; Isakova-Sivak I; Kuznetsova S; Larionova N; Desheva J; Dubrovina I; Nikiforova A; Victor JC; Neuzil K; Flores J; Tsvetnitsky V; Kiselev O.
            PLoS ONE [Electronic Resource]. 9(2):e87962, 2014.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24533064
            108. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
            Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arasteh K; Schurmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fatkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sorensen B.
            The Lancet Infectious Diseases. 14(4):291-300, 2014 Apr.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24525316
            109. A phase I clinical study of a live attenuated Bordetella pertussis vaccine–BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
            Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergstrom J; Ljungman M; Torner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C.
            PLoS ONE [Electronic Resource]. 9(1):e83449, 2014.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24421886
            110. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
            Behrens RH; Cramer JP; Jelinek T; Shaw H; von Sonnenburg F; Wilbraham D; Weinke T; Bell DJ; Asturias E; Pauwells HL; Maxwell R; Paredes-Paredes M; Glenn GM; Dewasthaly S; Stablein DM; Jiang ZD; DuPont HL.
            The Lancet Infectious Diseases. 14(3):197-204, 2014 Mar.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24291168
            111. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
            Harrer T; Plettenberg A; Arasteh K; Van Lunzen J; Fatkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G.
            Vaccine. 32(22):2657-65, 2014 May 07.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 24144472
            112. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
            Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B.
            Human vaccines & Immunotherapeutics. 10(1):170-83, 2014.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Observational Study. Randomized Controlled Trial]
            UI: 24064511
            113. Characteristics of vaccine failures in a randomized placebo-controlled trial of inactivated influenza vaccine in children.
            Ng S; Ni MY; Fang VJ; Ip DK; Chan KH; Leung GM; Peiris JS; Cowling BJ.
            Pediatric Infectious Disease Journal. 33(2):e63-6, 2014 Feb.
            [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 24061274
            114. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China.
            Li RC; Huang T; Li Y; Luo D; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH.
            Human vaccines & Immunotherapeutics. 10(1):11-8, 2014.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24013441
            115. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
            Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD.
            Journal of Infectious Diseases. 209(1):46-55, 2014 Jan 01.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 23922377
            116. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
            Bhattacharya SK; Sur D; Ali M; Kanungo S; You YA; Manna B; Sah B; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Dhingra MS; Donner A; Nair GB; Lopez AL; Wierzba TF; Clemens JD.
            The Lancet Infectious Diseases. 13(12):1050-6, 2013 Dec.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24140390
            117. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
            Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y.
            Vaccine. 31(49):5814-21, 2013 Dec 02.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24135573
            118. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
            Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Herve C; Descamps D.
            Vaccine. 31(48):5745-53, 2013 Nov 19.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24091311
            119. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.
            De Serres G; Skowronski DM; Wu XW; Ambrose CS.
            Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 18(37), 2013 Sep 12.
            [Comparative Study. Journal Article]
            UI: 24079398
            120. A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.
            Jackson A; Kloverpris HN; Boffito M; Handley A; Atkins M; Hayes P; Gilmour J; Riddel L; Chen F; Bailey-Tippets M; Walker B; Ackland J; Sullivan M; Goulder P.
            PLoS ONE [Electronic Resource]. 8(9):e73765, 2013.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 24069230
            121. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.
            Creech CB; Dekker CL; Ho D; Phillips S; Mackey S; Murray-Krezan C; Grazia Pau M; Hendriks J; Brown V; Dally LG; Versteege I; Edwards KM.
            Human vaccines & Immunotherapeutics. 9(12):2548-57, 2013 Dec.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 23955431
            122. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
            Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH.
            Human vaccines & Immunotherapeutics. 9(8):1638-42, 2013 Aug.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23807360
            123. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
            Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schodel F; Brown ML; Lawrence J.
            Human vaccines & Immunotherapeutics. 9(8):1626-33, 2013 Aug.
            [Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 23732903
            124. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
            Zhu FC; Meng FY; Li JX; Li XL; Mao QY; Tao H; Zhang YT; Yao X; Chu K; Chen QH; Hu YM; Wu X; Liu P; Zhu LY; Gao F; Jin H; Chen YJ; Dong YY; Liang YC; Shi NM; Ge HM; Liu L; Chen SG; Ai X; Zhang ZY; Ji YG; Luo FJ; Chen XQ; Zhang Y; Zhu LW; Liang ZL; Shen XL.
            Lancet. 381(9882):2024-32, 2013 Jun 08.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23726161
            125. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
            Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E.
            Vaccine. 31(30):3051-8, 2013 Jun 26.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 23701746
            126. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits.
            Kuschner RA; Russell KL; Abuja M; Bauer KM; Faix DJ; Hait H; Henrick J; Jacobs M; Liss A; Lynch JA; Liu Q; Lyons AG; Malik M; Moon JE; Stubbs J; Sun W; Tang D; Towle AC; Walsh DS; Wilkerson D; Adenovirus Vaccine Efficacy Trial Consortium.
            Vaccine. 31(28):2963-71, 2013 Jun 19.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 23623865
            127. Niccine, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial.
            Tonstad S; Heggen E; Giljam H; Lagerback PA; Tonnesen P; Wikingsson LD; Lindblom N; de Villiers S; Svensson TH; Fagerstrom KO.
            Nicotine & Tobacco Research. 15(9):1492-501, 2013 Sep.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23471101
            128. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
            Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H; MVA85A 020 Trial Study Team.
            Lancet. 381(9871):1021-8, 2013 Mar 23.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23391465
            129. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.
            Gurwith M; Lock M; Taylor EM; Ishioka G; Alexander J; Mayall T; Ervin JE; Greenberg RN; Strout C; Treanor JJ; Webby R; Wright PF.
            The Lancet Infectious Diseases. 13(3):238-50, 2013 Mar.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23369412
            130. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
            Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ.
            Lancet. 381(9871):1037-45, 2013 Mar 23.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23352749
            131. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
            Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A.
            AIDS. 27(3):369-79, 2013 Jan 28.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23032417
            132. The efficacy and safety of a nicotine conjugate vaccine (NicVAX) or placebo co-administered with varenicline (Champix) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.
            Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; Brauer R; Kessler PD; Kalnik MW; Fahim RE; van Schayck OC.
            BMC Public Health. 12:1052, 2012 Dec 06.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 23216646
            133. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults.
            Chichester JA; Jones RM; Green BJ; Stow M; Miao F; Moonsammy G; Streatfield SJ; Yusibov V.
            Viruses. 4(11):3227-44, 2012 Nov 19.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 23202523
            134. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
            Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL.
            PLoS ONE [Electronic Resource]. 7(8):e41936, 2012.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 22870265
            135. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
            Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH.
            Human vaccines & Immunotherapeutics. 8(6):806-12, 2012 Jun.
            [Clinical Trial, Phase IV. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22699440
            136. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
            Pleguezuelos O; Robinson S; Stoloff GA; Caparros-Wanderley W.
            Vaccine. 30(31):4655-60, 2012 Jun 29.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22575166
            137. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
            Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garces-Sanchez M; Martinon-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL; 2001 Study Investigators.
            The Lancet Infectious Diseases. 12(8):597-607, 2012 Aug.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22569484
            138. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
            Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD.
            Vaccine. 30 Suppl 1:A44-51, 2012 Apr 27.
            [Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 22520136
            139. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.
            Cunliffe NA; Witte D; Ngwira BM; Todd S; Bostock NJ; Turner AM; Chimpeni P; Victor JC; Steele AD; Bouckenooghe A; Neuzil KM.
            Vaccine. 30 Suppl 1:A36-43, 2012 Apr 27.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, P.H.S.]
            UI: 22520135
            140. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females.
            Li R; Li Y; Radley D; Liu Y; Huang T; Sings HL; Zhang L; Wang W; Zhong X; Saah AJ.
            Vaccine. 30(28):4284-91, 2012 Jun 13.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22433961
            141. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
            Li YP; Liang ZL; Gao Q; Huang LR; Mao QY; Wen SQ; Liu Y; Yin WD; Li RC; Wang JZ.
            Vaccine. 30(22):3295-303, 2012 May 09.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22426327
            142. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
            Santolaya ME; O’Ryan ML; Valenzuela MT; Prado V; Vergara R; Munoz A; Toneatto D; Grana G; Wang H; Clemens R; Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.
            Lancet. 379(9816):617-24, 2012 Feb 18.
            [Clinical Trial, Phase II. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 22260988
            143. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
            Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT.
            The Lancet Infectious Diseases. 12(4):290-9, 2012 Apr.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 22237175
            144. Horizontal transmission of a human rotavirus vaccine strain–a randomized, placebo-controlled study in twins.
            Rivera L; Pena LM; Stainier I; Gillard P; Cheuvart B; Smolenov I; Ortega-Barria E; Han HH.
            Vaccine. 29(51):9508-13, 2011 Nov 28.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t. Twin Study]
            UI: 22008819
            145. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.
            Harro C; Sack D; Bourgeois AL; Walker R; DeNearing B; Feller A; Chakraborty S; Buchwaldt C; Darsley MJ.
            Clinical & Vaccine Immunology: CVI. 18(12):2118-27, 2011 Dec.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 21994354
            146. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial.
            Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M.
            Vaccine. 29(44):7733-9, 2011 Oct 13.
            [Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 21835220
            147. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
            Lopez-Macias C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G.
            Vaccine. 29(44):7826-34, 2011 Oct 13.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 21816199
            148. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.
            Bernstein DI; Falloon J; Yi T.
            Vaccine. 29(40):7042-8, 2011 Sep 16.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 21782874
            149. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.
            Langley JM; Risi G; Caldwell M; Gilderman L; Berwald B; Fogarty C; Poling T; Riff D; Baron M; Frenette L; Sheldon E; Collins H; Shepard M; Dionne M; Brune D; Ferguson L; Vaughn D; Li P; Fries L.
            Journal of Infectious Diseases. 203(12):1729-38, 2011 Jun 15.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 21606531
            150. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
            Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG; HVTN 503/Phambili study team.
            The Lancet Infectious Diseases. 11(7):507-15, 2011 Jul.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 21570355
            151. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.
            Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O’Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK.
            Lancet. 377(9773):1256-63, 2011 Apr 09.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 21481708
            152. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).
            Fitzgerald DW; Janes H; Robertson M; Coombs R; Frank I; Gilbert P; Loufty M; Mehrotra D; Duerr A; Step Study Protocol Team.
            Journal of Infectious Diseases. 203(6):765-72, 2011 Mar 15.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 21343146
            153. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial.
            Barrett PN; Berezuk G; Fritsch S; Aichinger G; Hart MK; El-Amin W; Kistner O; Ehrlich HJ.
            Lancet. 377(9767):751-9, 2011 Feb 26.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, U.S. Gov’t, P.H.S.]
            UI: 21329971
            154. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial.
            Davidson LE; Fiorino AM; Snydman DR; Hibberd PL.
            European Journal of Clinical Nutrition. 65(4):501-7, 2011 Apr.
            [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 21285968
            155. Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: a randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age.
            Matsuda F; Chowdhury MI; Saha A; Asahara T; Nomoto K; Tarique AA; Ahmed T; Nishibuchi M; Cravioto A; Qadri F.
            Vaccine. 29(10):1855-8, 2011 Feb 24.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 21236234
            156. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.
            Biedenbender R; Bevilacqua J; Gregg AM; Watson M; Dayan G.
            Journal of Infectious Diseases. 203(1):75-84, 2011 Jan 01.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 21148499
            157. Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers.
            Udani JK; Singh BB; Barrett ML; Singh VJ.
            Nutrition Journal. 9:32, 2010 Aug 26.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20796315
            158. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
            Zhu FC; Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Wang H; Yang CL; Jiang HM; Cai JP; Wang YJ; Ai X; Hu YM; Tang Q; Yao X; Yan Q; Xian YL; Wu T; Li YM; Miao J; Ng MH; Shih JW; Xia NS.
            Lancet. 376(9744):895-902, 2010 Sep 11.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20728932
            159. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
            Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schodel F; Steele AD; Neuzil KM; Ciarlet M.
            Lancet. 376(9741):615-23, 2010 Aug 21.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20692031
            160. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
            Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schodel F; Ciarlet M; Neuzil KM.
            Lancet. 376(9741):606-14, 2010 Aug 21.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20692030
            161. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
            Schooley RT; Spritzler J; Wang H; Lederman MM; Havlir D; Kuritzkes DR; Pollard R; Battaglia C; Robertson M; Mehrotra D; Casimiro D; Cox K; Schock B; AIDS Clinical Trials Group 5197 Study Team.
            Journal of Infectious Diseases. 202(5):705-16, 2010 Sep 01.
            [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural]
            UI: 20662716
            162. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
            Salmon-Ceron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelievre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Levy Y; Launay O; ANRS VAC18 trial group.
            AIDS. 24(14):2211-23, 2010 Sep 10.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20625264
            163. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.
            Jackson LA; Gaglani MJ; Keyserling HL; Balser J; Bouveret N; Fries L; Treanor JJ.
            BMC Infectious Diseases. 10:71, 2010 Mar 17.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20236548
            164. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.
            Maruyama T; Taguchi O; Niederman MS; Morser J; Kobayashi H; Kobayashi T; D’Alessandro-Gabazza C; Nakayama S; Nishikubo K; Noguchi T; Takei Y; Gabazza EC.
            BMJ. 340:c1004, 2010 Mar 08.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 20211953
            165. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.
            Lyon CE; Sadigh KS; Carmolli MP; Harro C; Sheldon E; Lindow JC; Larsson CJ; Martinez T; Feller A; Ventrone CH; Sack DA; DeNearing B; Fingar A; Pierce K; Dill EA; Schwartz HI; Beardsworth EE; Kilonzo B; May JP; Lam W; Upton A; Budhram R; Kirkpatrick BD.
            Vaccine. 28(20):3602-8, 2010 Apr 30.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 20188175
            166. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
            Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD; GRC28 Study Team.
            Pediatric Infectious Disease Journal. 29(2):105-10, 2010 Feb.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19934787
            167. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.
            Vilaplana C; Montane E; Pinto S; Barriocanal AM; Domenech G; Torres F; Cardona PJ; Costa J.
            Vaccine. 28(4):1106-16, 2010 Jan 22.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19853680
            168. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
            GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A.
            Lancet. 374(9706):1975-85, 2009 Dec 12.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 19962185
            169. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
            Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM.
            Journal of Infectious Diseases. 200(12):1861-9, 2009 Dec 15.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19909082
            170. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
            Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD.
            Lancet. 374(9702):1694-702, 2009 Nov 14.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19819004
            171. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
            Martell BA; Orson FM; Poling J; Mitchell E; Rossen RD; Gardner T; Kosten TR.
            Archives of General Psychiatry. 66(10):1116-23, 2009 Oct.
            [Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t. Research Support, U.S. Gov’t, Non-P.H.S.]
            UI: 19805702
            172. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
            Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D.
            Vaccine. 27(49):6887-93, 2009 Nov 16.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19761838
            173. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
            Valera R; Garcia HM; Jidy MD; Mirabal M; Armesto MI; Fando R; Garcia L; Fernandez R; Ano G; Cedre B; Ramirez M; Bravo L; Serrano T; Palma S; Gonzalez D; Miralles F; Medina V; Nunez F; Plasencia Y; Martinez JC; Mandarioti A; Lugones J; Rodriguez BL; Moreno A; Gonzalez D; Baro M; Solis RL; Sierra G; Barbera R; Dominguez F; Gutierrez C; Kouri G; Campa C; Menendez J.
            Vaccine. 27(47):6564-9, 2009 Nov 05.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 19720365
            174. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus.
            Anderson JS; Hoy J; Hillman R; Barnden M; Eu B; McKenzie A; Gittleson C.
            Journal of Acquired Immune Deficiency Syndromes: JAIDS. 52(3):371-81, 2009 Nov 01.
            [Clinical Trial, Phase I. Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 19661810
            175. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.
            Breiman RF; Brooks WA; Goswami D; Lagos R; Borja-Tabora C; Lanata CF; Londono JA; Lum LC; Rappaport R; Razmpour A; Walker RE; Gruber WC; Forrest BD.
            Vaccine. 27(40):5472-9, 2009 Sep 04.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19616493
            176. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.
            Bhandari N; Sharma P; Taneja S; Kumar T; Rongsen-Chandola T; Appaiahgari MB; Mishra A; Singh S; Vrati S; Rotavirus Vaccine Development Group.
            Journal of Infectious Diseases. 200(3):421-9, 2009 Aug 01.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19545211
            177. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
            Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK.
            Vaccine. 27(35):4850-6, 2009 Jul 30.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19523608
            178. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.
            Lucero MG; Nohynek H; Williams G; Tallo V; Simoes EA; Lupisan S; Sanvictores D; Forsyth S; Puumalainen T; Ugpo J; Lechago M; de Campo M; Abucejo-Ladesma E; Sombrero L; Nissinen A; Soininen A; Ruutu P; Riley I; Makela HP.
            Pediatric Infectious Disease Journal. 28(6):455-62, 2009 Jun.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19483514
            179. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
            Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC.
            Journal of Medical Virology. 81(5):908-14, 2009 May.
            [Journal Article. Multicenter Study. Randomized Controlled Trial]
            UI: 19319953
            180. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example.
            Beran J; Wertzova V; Honegr K; Kaliskova E; Havlickova M; Havlik J; Jirincova H; Van Belle P; Jain V; Innis B; Devaster JM.
            BMC Infectious Diseases. 9:2, 2009 Jan 17.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19149900
            181. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
            Launay O; Sadorge C; Jolly N; Poirier B; Bechet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML.
            Vaccine. 27(8):1184-91, 2009 Feb 18.
            [Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 19135496
            182. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
            Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; Del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN; Step Study Protocol Team.
            Lancet. 372(9653):1881-1893, 2008 Nov 29.
            [Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 19012954
            183. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study.
            Phua KB; Quak SH; Lim FS; Goh P; Teoh YL; Datta SK; Han HH; Bock HL.
            Annals of the Academy of Medicine, Singapore. 37(7):546-53, 2008 Jul.
            [Clinical Trial. Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial]
            UI: 18695765
            184. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.
            McKenzie R; Darsley M; Thomas N; Randall R; Carpenter C; Forbes E; Finucane M; Sack RB; Hall E; Bourgeois AL.
            Vaccine. 26(36):4731-9, 2008 Aug 26.
            [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov’t]
            UI: 18602960
            185. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
            Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenbock A; Sun W; Lyons A.
            Journal of Infectious Diseases. 198(4):493-9, 2008 Aug 15.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18588481
            186. Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial.
            Benn CS; Diness BR; Roth A; Nante E; Fisker AB; Lisse IM; Yazdanbakhsh M; Whittle H; Rodrigues A; Aaby P.
            BMJ. 336(7658):1416-20, 2008 Jun 21.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18558641
            187. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
            Mahalanabis D; Lopez AL; Sur D; Deen J; Manna B; Kanungo S; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Rao R; Holmgren J; Clemens J; Bhattacharya SK.
            PLoS ONE [Electronic Resource]. 3(6):e2323, 2008 Jun 04.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18523643
            188. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults.
            Bethony JM; Simon G; Diemert DJ; Parenti D; Desrosiers A; Schuck S; Fujiwara R; Santiago H; Hotez PJ.
            Vaccine. 26(19):2408-17, 2008 May 02.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial]
            UI: 18396361
            189. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
            Linhares AC; Velazquez FR; Perez-Schael I; Saez-Llorens X; Abate H; Espinoza F; Lopez P; Macias-Parra M; Ortega-Barria E; Rivera-Medina DM; Rivera L; Pavia-Ruz N; Nunez E; Damaso S; Ruiz-Palacios GM; De Vos B; O’Ryan M; Gillard P; Bouckenooghe A; Human Rotavirus Vaccine Study Group.
            Lancet. 371(9619):1181-9, 2008 Apr 05.
            [Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18395579
            190. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
            Wagena EJ; de Vos A; Horwith G; van Schayck CP.
            Nicotine & Tobacco Research. 10(1):213-8, 2008 Jan.
            [Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18188762
            191. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects.
            Kang S; Kim KH; Kim YT; Kim YT; Kim JH; Song YS; Shin SH; Ryu HS; Han JW; Kang JH; Park SY.
            International Journal of Gynecological Cancer. 18(5):1013-9, 2008 Sep-Oct.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 17986242
            192. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
            Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Leonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M.
            Journal of Infectious Diseases. 196(12):1749-53, 2007 Dec 15.
            [Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 18190254
            193. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
            Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R.
            PLoS ONE [Electronic Resource]. 2(10):e1018, 2007 Oct 10.
            [Clinical Trial, Phase I. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 17925866
            194. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.
            Doring G; Meisner C; Stern M; Flagella Vaccine Trial Study Group.
            Proceedings of the National Academy of Sciences of the United States of America. 104(26):11020-5, 2007 Jun 26.
            [Clinical Trial, Phase III. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 17585011
            195. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.
            Cuba IPV Study Collaborative Group.
            New England Journal of Medicine. 356(15):1536-44, 2007 Apr 12.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 17429085
            196. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
            Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K; Bangkok Vaccine Evaluation Group.
            Journal of Infectious Diseases. 194(12):1661-71, 2006 Dec 15.
            [Clinical Trial. Clinical Trial, Phase I. Clinical Trial, Phase II. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 17109337
            197. Effect of probiotics on vaccine antibody responses in infancy–a randomized placebo-controlled double-blind trial.
            Kukkonen K; Nieminen T; Poussa T; Savilahti E; Kuitunen M.
            Pediatric Allergy & Immunology. 17(6):416-21, 2006 Sep.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 16925686
            198. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
            Colas C; Monzon S; Venturini M; Lezaun A.
            Journal of Allergy & Clinical Immunology. 117(4):810-6, 2006 Apr.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 16630938
            199. Randomised, placebo-controlled trial of a live vaccine against porcine reproductive and respiratory syndrome virus in sows on infected farms.
            Pejsak Z; Markowska-Daniel I.
            Veterinary Record. 158(14):475-8, 2006 Apr 08.
            [Journal Article. Randomized Controlled Trial]
            UI: 16603552
            200. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
            Firbas C; Jilma B; Tauber E; Buerger V; Jelovcan S; Lingnau K; Buschle M; Frisch J; Klade CS.
            Vaccine. 24(20):4343-53, 2006 May 15.
            [Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov’t]
            UI: 16581161

          • @Angel and Kandace

            For some (technical) reason I haven’t been able to upload part three of the reference list. Papers 201 through 258 are the oldest examples of the genre (dating back to the 1960s).

            It would be so nice if anti-vaxxers could inform themselves of the realities before posting rumours and unevidenced nonsense in comments.

          • @Frank Odds

            The problem with the studies you provided (and didn’t read) is that they don’t use a TRUE placebo.

            Here is a quote from the first study. Note the final sentance:

            Vaccine or placebo were administered as 0.5-mL intramuscular injections on Day 1 and at Months 2 and 6. Each dose of the qHPV vaccine contained HPV6/11/16/18 L1 viral-like particles 20/40/40/20 µg, respectively, and 225 µg aluminum (as aluminum hydroxyphosphate sulfate adjuvant). The placebo doses contained the adjuvant alone.

            The adjuvant is what contains substances such as aluminum or mercury, which is what those who are speculative about vaccine safety are usually concerned about. Since both the test and control groups receive the adjuvant, the safety of the adjuvant, and therefore the vaccine as a whole, is not being tested.

  • As HP is being given to normal individuals before infection then according to homeopathy it should induce symptoms of the disease, as it doesn’t it thus ‘proves’ homeopathy doesn’t work.

    It also throws away any allegiance of homeopaths to their much vaunted individualisation which they claim invalidates most of the negative clinical trials.

    This part of homeopathy shows it to clearly be a scam and a dangerous practice which should be outlawed.

  • “why are they not fined for advertising and promoting this fake vaccine to replace scientifically and clinically proven vaccines?” Where do you get such studies? I would love to hear this… because those studies just do not exist. You are uninformed and follow a mainstream mass conception. Thát’s dangarous. As are toxic vaccines.

    • Where do you get such studies? I would love to hear this… because those studies just do not exist.

      Please take a look at this link for a start.

      The Cochrane database lists 52 systematic reviews of vaccine clinical trials (that’s reviews of multiple studies of the type you say ‘just do not exist’)

      A search of Medline for the keywords ‘vaccine’ and ‘clinical trial’ produced 11,826 hits, indicating the true scope of the studies you claim ‘just do not exist’.

      Happy to fulfil your ‘love to hear this’ request.

  • This write up does nothing to show any proof that homeoprophylaxis is false. Instead, he attacks her education and calls her a quack with no foundation to this writing to back himself up.

    To be clear…
    Homeoprophylaxis is not biologically plausible. How so? You did not back this up with anything whatsoever. Prove your thesis.

    There is no evidence that it works. Really? Have you even looked, or are you just being mainstream and whining about something that is undermining the $$ you get from giving ‘real’ vaccines with dangerous adjuvents in them.. hmmm..
    And if you HAVE looked, where is that evidence that it DOESN’T work? The writer of this article is leaving this article incomplete without said evidence.

    The last two of your ‘to be clear’ are opinions with no backup. Homeoprophylaxis has been around for over 100 years, it is NOT NEW. There should be something for you to express yourself better here. And no, I am no anti-vaxxer, but someone who likes truth in reporting. You can do better than this!

    • what a comment!
      yes I have looked
      and no, we do not have to prove that anything does not work in medicine – it is the other way round.
      why don’t you familiarise yourself with the basics before commenting nonsense?

      • It’s not like that in a court of law…which is what all $$$pharmaceutical companies$$$ hide behind. They’re always innocent until proven guilty. You can only prove their drugs work in a lab and stupid “double blind” placebo controlled studies. Have you ever taken an experimental psychology course or quantitive/qualitive statistics and analysis course? It can’t really be done… it’s not translatable to real life. There’s physics, entropy, and energy in everything. It transfers…to cellular levels. That’s how this works

        • congratulations!
          you have just realised that healthcare is not a court of law and functions differently

        • Quote: “Have you ever taken an experimental psychology course or quantitive/qualitive statistics and analysis course?” well, yes, I took the latter. Actually I am a computational biologist and that is a hell lot more stats than just one course. Actually I *work* in that field at a university and have published peer reviewed papers. I have seen hundreds of studies. You are correct, RCTs don’t really reflect real life. They reflect ideal conditions. In that sense, results (especially effect sizes) in RCTs tend to get smaller in real life conditions. I have never seen an effect in a real life setting that was not detectable in an RCT. If such happens, something went really wrong with your observational study design.

          And no, homeopathy does not translate into entropy, energy and everything. In fact it violates these very theories to the core. And no, Judy, homeopathy does NOT work.

        • @Judy

          There’s physics, entropy, and energy in everything. It transfers…to cellular levels. That’s how this works.

          Thank you for this erudite explanation. It will surely augment and enhance understanding of medicine.

      • Oh man I just need to get off this page. Obviously Edzard, with all of his “education”, has not had any mentors coaching his soft skills. Edzard, familiarize yourself with the basics of communicating to a blog audience and establishing common ground. You are doing nothing but make people sink their heals into their established beliefs. And yes, the medical field has many thought filters and disfunctional paradigms. Thankfully a paradigm shift is occurring in the field. But, I’ve yet to meet another Dr. who has read Thomas Kuhn’s The Structure of Scientific Revolutions.

    • jesusknight said:

      There is no evidence that it works. Really? Have you even looked, or are you just being mainstream and whining about something that is undermining the $$ you get from giving ‘real’ vaccines with dangerous adjuvents in them.. hmmm..

      What $$ are they then? And have you any clue about Prof Ernst?

      But ‘vaccines with dangerous adjuvents in them’… You did not back this up with anything whatsoever. Prove your thesis.

      Homeoprophylaxis has been around for over 100 years, it is NOT NEW.

      LOL! But if you believe homeoprophylaxis ‘works’, please feel free to present your evidence.

      • I never said I believed in homeoprophylaxis, or even in anti-vaxxing. I am neither. And, I never knew what the former was until just before I came to this site. I was suggesting that he back up his claim that it is false, period. I came for info – not propaganda – either way.

        What do you mean, you don’t have to prove that anything doesn’t work in medicine? Are you nuts? Then what in the world are trials for, if not to prove (or disprove) what is being tested?

        • “… back up his claim that it is false…”
          it is false because there is no evidence to support it – is that so difficult to understand?

        • @jesusknight

          “What do you mean, you don’t have to prove that anything doesn’t work in medicine? Are you nuts? Then what in the world are trials for, if not to prove (or disprove) what is being tested?”

          The way the scientific process works, as you clearly understand, is for someone to do experiments to investigate their hypothesis. (Experiments are ideally designed to disprove the hypothesis.) That’s the way we try to distinguish reality from nonsense. But please note, it is for the proposer of a hypothesis to do the experiments (and to do them well): anyone can suggest an idea then say “prove I’m wrong!”

          That’s why your initial comment provoked a strong negative reaction: you’re asking other folk to prove someone’s belief/theory is wrong, and that’s not how things work in science. If you make a claim (e.g. that homeoprophylaxis works) you need to supply the evidence to back up the claim. In the case of homeoprophylaxis there is zero supportive evidence.

          You asked a perfectly fair question, which I hope I’ve now answered.

        • jesusknoght said

          I never said I believed in homeoprophylaxis

          I never said you did. I said if you believe…

          Frank and Edzard have answered the rest of your comment.

    • Well, jesusknight, Hahnemann himself propagated Belladonna as homeoprophylaxis against scarlet fever. This was a HUGE hype in the 19th century – that is until JW Begbie looked into the mortality – which did NOT drop. That is a very robust proof that homeoprophylaxis does not work.

      Aside that quote: “And if you HAVE looked, where is that evidence that it DOESN’T work?” It doesn’t work like this. YOU have to prove it works.

    • Anothher thing, jesusknight. If you think about undermining $$ one gets from vaccines, well. Boiron (one of the biggest manufacturers of homeopathic drugs) has a profit margin of 20%, i.o.w. exactly as a normal pharma company. It has a far better profit/risk ratio because there is no risky research expenses involved. In fact, some stakeholders of pharmaceutical companies hold stakes in homeopathic companies. Homeopathy works *exactly* as the normal pharma industry, or as Natalie Grams put it: Globuli are not brushed down from biologically raised trees.

      • The worth of Boiron stocks has been increasing almost relentlessly for years. There was a small setback in 2012 when they had to pay millions of dollars to settle a class-action lawsuit in the US because they couldn’t prove homeopathy works! After that their stocks have been increasing in worth at a far greater rate than big pharma.

        Have a look at Bloomberg Markets for Boiron stocks Choose a five year diagram and try entering some pharma-companies in the comparison field. For example Merk ( MRK:US), Pfizer (PFE:US) and Glaxo (GSK:US).
        You will see that Big Homeo seems to be a very much more lucrative business. Not the least considering the only bulk raw materials they need is water and sugar and their R/D consists mostly of paying homeopaths to write up biased made-for-marketing studies in homeopathy journals.

  • Edzar, dear – step back & take a broad look at your training in medicine and the wellness movement that is growing by leaps & bounds. Most of the world uses homeopathy and other nontoxic ways to promote true health & wellness. Homeopathy is used successfully with animals – so the healing affect is certainly not a placebo. This world can be seen from the FEAR perception or the LOVE perception. Your entire training was fear-based as can be felt through your raised blood pressure comment. The majority of your colleagues die quite young and the FDA admits that iatrogenic causes (just following doctors’ advice) are responsible for most deaths in the USA and that this generation will not outlive their parents. Vaccines are the lynchpin of these statistics and of the epidemic proportions of all manner of disease, dysfunction, early death, & destruction of the family & society.
    There are no secrets from people who CHOOSE to use their Divinely provided brain. The US govt allowed Nazi scientists to continue their immoral & corrupt science thru pHARMa that also originated in Nazi germany. When you don’t discern what is evil & stand up against it – you get swallowed up by it and become not so different.
    As long as you’re alive – you have the opportunity to seek humility, wisdom, & love…the truth always wins – are you so sure that your fear-based stance has more than a speck of truth?
    Wake up! Stop adding to the anguish of countless families! Check out the wisdom of the cells & the biology of belief.

    • Edzar, dear
      MY NAME IS EDZARD
      Most of the world uses homeopathy and other nontoxic ways to promote true health
      THAT DOES NOT MEAN THAT IT IS EFFECTIVE
      Homeopathy is used successfully with animals
      NO, IT ISN’T! (http://edzardernst.com/2016/12/and-again-no-good-evidence-that-homeopathy-works-in-animals/)
      the healing affect is certainly not a placebo
      BUT IT IS A PLACEBO! http://edzardernst.com/2015/03/the-final-verdict-on-homeopathy-its-a-placebo/
      THIS IS WHERE I STOPPED READING YOUR COMMENT – IT WAS TOO DAFT FOR MY TASTE.

    • Sara, you’re so full of BS, you urgently need to get your septic tank emptied.

      You wrote:

      the FDA admits that iatrogenic causes (just following doctors’ advice) are responsible for most deaths in the USA

      In fact, the FDA says : “Medication errors cause at least one death every day and injure approximately 1.3 million people annually in the United States.” So that’s hundreds of deaths per year, compared with (deaths per year):
      Heart disease: 633,842
      Cancer: 595,930
      Chronic lower respiratory diseases: 155,041
      Accidents (unintentional injuries): 146,571
      Stroke (cerebrovascular diseases): 140,323
      Alzheimer’s disease: 110,561
      Diabetes: 79,535
      Influenza and Pneumonia: 57,062
      Nephritis, nephrotic syndrome and nephrosis: 49,959
      Intentional self-harm (suicide): 44,193
      (Source, CDC statistics at https://www.cdc.gov/nchs/fastats/deaths.htm)

      You wrote

      Vaccines are the lynchpin of these statistics and of the epidemic proportions of all manner of disease, dysfunction, early death, & destruction of the family & society.

      And yet, if you look here, even a sad mind like yours should be able to see your claim is absurd.

      You wrote:

      There are no secrets from people who CHOOSE to use their Divinely provided brain.

      I’d love to see your evidence that people’s brains are ‘provided’ by any sort of divinity, but the output from yours is concrete proof of cerebral malfunction.

      You wrote:

      Check out the wisdom of the cells & the biology of belief.

      “Men willingly believe what they wish.” (Julius Caesar) That’s why belief is so desperately inadequate for establishing any kind of reality. Your beliefs are so far wide of the mark that, like quicksand, they’ll drown you very fast without some kind of help.

    • PS: Thank you for the splendid proof of Godwin’s Law:

      The US govt allowed Nazi scientists to continue their immoral & corrupt science thru pHARMa that also originated in Nazi germany.

    • Sara: “[wharrrgarble]”

      Proof positive that homeopathic anti-psychotics are incredibly effective*

      (*at separating lunatics from their money)

    • Edzard – oh wow the air.

  • I apologize Edzard for the typo. In such a crucial topic that is destroying society – it would be people with so many degrees with their heads so full of high filutent data who are the most likely to get distracted by their names being spelled incorrectly….covering up for simply breathtaking ignorance in the likes of yourself & your cronies is even more spectacular arrogance…,& right you are about “belief” – what you CHOOSE to believe is YOUR truth & NOT objective truth. My subjective truth that is a LOVE-based truth has the overwhelming evidence that it is aligned with the ONE objective & G-dly truth. When you are full of EGO – you Ease G-d Out.
    For Frank – we don’t live in the dark ages – when you begin to humbly seek the truth & go through the discomfort of confronting your erroneous & quite immature beliefs – the way you address another human being will become more human & refined. I know. You’re not there yet. Take a look at the mind valley website as well as other sites like my high vibrational life.
    Why shouldn’t you aim to get what you truly desire – but you first need to learn. Don’t sabotage your own self. There’s much more to life than belittling others with your sad state of ignorance.

    • Sara,

      you may believe and hold for truth whatever you want, e.g. that the sun rises in the west. If you see – after years of observation – that the sun never rose in the west, it is pretty safe to assume that your believe does NOT reflect the truth.

      The same goes for homeopathy. It has been thoroughly debunked. Your statement that we do not live in the dark ages is correct. Homeopathy in fact *is* a cult that came straight out of the dark ages.

    • Jesus.

      What a load of complete and utter bollocks. Makes a Bryan Hubbard WDDTY column seem rational by comparison.

      You carry on believing, sweetikins. We’ll carry on living in the real world.

  • We’ve been using HP as a family for 2 years now, right after my youngest was born. Every time I give my children the nosodes they always show a reaction, which means HP is working. The proof is in the pudding.

    • no, the placebo is in the pudding; the proof is in science.

    • The overly dilute nosodes (or whatever else) does nothing. Try giving the pudding without the nosodes a few times and you will get the same results. If you are rational enough and not too much of a wishful thinker, the striking similarity in outcomes might help you understand why there is no difference (because there is nothing in the preparations) and that you have spent too much money in something that does not exist.

    • @E
      Of course you don’t have to vaccinate all your children, only those you wish to keep!

      You can of course continue to rely on shaken water and feel smugly superior in your selfish flower-decorated bubble depending on everyone else around you keeping polio, measles or whatever ugly bugs away from your pure unvaccinated little snowflakes. But if and when disaster hits, you will be faced with your ignorant choice based on lies and denial. Perhaps then you will want to read Roald Dahl’s account of the time he lost his seven year old daughter to measles. This was in 1962, a few years before the measles vaccine became available:
      http://www.roalddahl.com/roald-dahl/timeline/1960s/november-1962

  • That’s an extremely sad story Roald Dahl shared. As tragic as this story is, it has nothing to do with the conversation. His poor daughter had absolutely nothing on her side to help her immune system fight the measles. The discussion, I thought, was about using vaccines or HP to protect against infectious disease. I realize after reading the comments that followed my own that I think there’s a misunderstanding of how HP works. It seems that people have a misconception that HP claims to be a vaccine, in which there’s never been such a claim. Instead of creating an immunity, it actually teaches your immune system how to fight the infectious disease if you ever come in contact with it.

    It’s very sad how people that have gotten on this conversation find it necessary to bash each other’s beliefs and intellect, but in the end we are our own people who need to decide what’s best for ourselves. My simple comment about “the proof is in the pudding” was not at all me trying to be smug or trying to confuse anyone, I was only trying to simply state that sometimes you just need to see it for yourself. It’s just an old turn of phrase, it has nothing to do with pudding in this case, which I think one person was confused that it had. In this case the phrase simply means “seeing is believing”. That being said, the commenter that corrected this old phrase to “the proof is in the science”, although I admit it just doesn’t have the same ring to it as the original, but is also true. When scientists conduct studies to prove or disprove, “seeing is believing” aka “the proof is in the pudding”.

    • Smite me… You seem to be a very reasonable person. Who on earth convinced you that homeopathy “teaches your immune system how to fight the infectious disease”? This is a sugar-coated fraud. Homeopathy does nothing and this has been established through robust evidence and properly controlled observations that transcend belief-based conclusions. What you are experiencing is random chance and coincidences…

      …and the very well-established fact that humans have a very strong immune system to begin with!

      Please, do not make the mistake to trust the health of your infants and children in “homeopathy and its kindred delusions”. This is an urge!

  • You say there is no evidence to prove that homeoprophylaxis works. That is only because you don’t want to see it. Entire countries have used it (having been issued from those countries versions of the CDC) to completely irradicate diseases! Yet another article written by someone so heavily brainwashed by pharmaceutical companies. Stop spreading your nonsense. I’m not interested in debating with people so will not be responding to ANY responses. Just thought you should know this person is talking utter crap and will no doubt take down this post as it is not in their interest to have the truth out there.

  • “This has the potential to kill thousands.” unlike conventional vaccines which has killed/ maimed thousands

    • unless you can provide evidence for your statement, we will have to assume that it was a deliberate stupidity to defame the already infamous anti-vax movement.

  • Gosh! What a rabid conversation.
    Years ago I looked up the 1918 flu epidemic and homeopathic interventions. My recollection is that the % of deaths in the population following medical advice was much higher than the population using homeopathy.

    On a personal side, I suppose the effects I experience using homeopathics might have something to do with some placebo effect, however when I have a cold and I take a homeopathic remedy for a specific symptom what happens to me is that that symptom goes away and another shows up. I take a remedy for the next symptom which then goes away and another shows up. This goes on for a few days and then I wake up feeling well i.e. no symptoms.

    I’m thinking that IF my recovery is due to a placebo effect (and If I am correct that the placebo affects the brain and brings health or a change in symptoms due to my brain thinking in am getting well) I would go from feeling a symptom to being symptom free (as that is my goal) without the shifting symptoms that I experience in between waking up with a scratchy threat and waking up well later.

    I suppose Docs will say that colds go away, no matter what, in some number of days. This is true as our systems are continuously working to keep us healthy and balanced at all times. However in the past 30 years if I get a cold away from home and my homeopathics it sure takes a lot more Kleenex and days of feeling sick for me to finally awaken feeling well again.

    This may not specifically address homeoprophylaxis, however for those of us who live our lives aiming for wellness, (and having no reason to visit a doctors office more than once a year for our annual checkup) for those of us who use no pharmicudical drugs, but do use the health support of time tested herbs and homeopathic remedies and flower essence remedies the results of our healthy living can not be catagorized as nothing more than mind over body. I don’t know enough about the potential effects of the remedies I use to be able to predict what specific effect they will have, so my mind can’t choose what placebo effect to create.

    As a final thought, I do check on and have seem that “natural” remedies can have side effects and interactions with other substances, however I have never seen a natural remedy with the kind of listing of dangerous side effects that we can see any day in commercials for miracle drugs. It makes sense for me to always use/try the most natural way to regain health.

    • Taking supplements or herbs to boost ones immune system and shorten the duration of a cold is very different from what is being discussed here.. Of course a healthy person is less apt to contract a cold. There are many illnesses the body can naturally fight. The common cold is an example of this. It is the BIG diseases that the body alone can not fight, the diseases that have wiped out many people over the centuries that are the concern. I have been searching for REAL scientific evidence from an unbiased source to prove homeoprophylaxis works and I am unable to find such research. I would LOVE to see evidence and would love an alternative to modern vaccines. I believe in the effectiveness of vaccination I just wish there were purer vaccines available to us. Still I continue to get vaccinated to prevent the potential spread of a disease that could kill many.

      • “I just wish there were purer vaccines available to us”. I wonder what you mean by ‘purity’ in the context of vaccines, Denise.

  • Here us a little a little something on Edzard Ernst, at the bottom are other articles on this person, always check the background folks, looks like he, like most of these pushers of mainstream science, they all have their dodgey background. You watch, eventually a money trail from some mainstream entity will be found between him and them.
    http://chiropracticlive.com/why-should-anyone-believe-what-professor-edzard-ernst-says-after-he-put-his-name-to-a-bbc-programme-he-now-describes-as-deception/

  • I’m a CHRISTian and commanded to test everything in an age where information has increased as prophesied in the Old Testament. Many lies and the love of money is the root of every kind of evil, is one explanation GOD gives us.

    This is why I distrust Big Pharma and their “studies.”

    “Immune” from lawsuits.
    Short window for lawsuits.
    Sealed documents.
    Loophole in sueing them closed by SCOTUS by saying vaccines are unavoidably unsafe.
    Studies are not done to test multiple vaccines by different manufacturers, and this is a guess, because adverse results would be blamed on the other guy.
    CDC has a monetary stake in many vaccines so there is s conflict of interest.
    The history of vaccines is dubious at best giving credit where none is due. Before a comment is made on that I will offer an analogy. Just like when doctors began washing their hands outcomes for patients improved, it was the improvements in clean water, better sewage and plumbing that reduced infectious diseases that vaccines got the credit for. That is a historic fact, but men lie about history also.

    Science – who should I trust. Dr Paul Thomas who wrote the Vaccine Friendly Plan, not anti vaccination at all, had a study done on his patients. By far the healthiest with the fewest visits are his completely unvaccinated patients I believe with 1 artistic in 700+, 2nd the partially vaccinated and lastly those vaccinated according to the CDC schedule – same dismal autism rate as stated by the very same CDC, I believe currently 1 in 50. Poor kids and parents. By the way he truly believes in informed consent and not bullying you into vaccinations with half the story because he has looked at the science.

    HP like it or not it is more in line with how people, who have life long immunity, got viruses historically, either orally or inhaled. Vaccinations come with lots of things, adjuvants, otherwise never part of how viruses historically were spread. And if it ever happened in history when did populations ever get 2 or more viruses at the same time?

    Hope this helps someone. Please consider these things.

    • why don’t you show us some good evidence that HP works?

      • Hi Edzard,

        I’m not GOD so I don’t know everything but where is the evidence of its failings? There are many for vaccines. I’m certain you know them.

        Thanks for reading my post. I agree there should be evidence but who decides what is evidence or what kind of testing or trials. If the vaccine manufacturers lie in their testing, and they have, and the reporting they do they cut their legs out from under themselves. You don’t get sued to the tune of over 40 billion for nothing. For example no true inert placebo but instead using another vaccine to skew results. They also use short test periods in line with the small windows from vaccine to injury. How long would it take to test the current CDC schedule with all the doses? They may have convinced you and many others but just another lie I hope is fully exposed soon. I hope Del Bigtree is successful in his attempt to have a real debate with the pharna giants and top pro vaxers. I don’t think they’ll do it though and chance the exposure.

        Maybe it’s because I am tired playing dad to my granddaughter and doing things more naturally to get my parents off the meds that have hurt them, even stopping my mom’s heart and putting her in the ER, but I believe you cited a source, assessed it and gave no evidence for your assertions. No need to give them to me while I was not pro vaccine nor antivax I like most trusted the sources that I no longer trust. The 30+ billion law suits for lying to the Fed government in addition to other facts that have come to light are enough. HP is at least if not more safe since the virus is more attenuated and void of adjuvants. Boosters reveal no lifelong immunity in vaccines. And you loose the life long benefits of the natural course of getting and getting over viruses.

        Frank is right, GOD hates murder but also injury and requires restitution. The vaccine manufacturers have murdered and injured hundreds of thousands with real restitution not possible for the vast majority.

        Why do I mention GOD so much? Because HE made all this possible, no I don’t blame HIM for it for HE did not force anyone to do evil, and as HE says, vengeance is mine. Justice won’t be had here but will be served in eternity. Thanks for your post but I couldn’t disagree with you more.

        • 30+ billion law suits for lying to the Fed

          That’s 100 lawsuits for every citizen of the US, isn’t it?

          • Pardon me I left out the word dollar.

          • Pardon me I left out the word dollar

            I can only reply to what you said, not what you think you said. There is a difference between what ought to be and what is, but I don’t think you understand the distinction.

          • @Joe

            The 30+ billion dollars you quote is irrelevant to anything, Joe. That’s just the figure that optimistic (greedy?) plaintiffs are trying to claim through courts of law. And courts of law have not proved to be reliable or even relevant when it comes to judging matters of science. Their decisions are based on verbal disputes, not dependable evidence.

    • “when did populations ever get 2 or more viruses at the same time”
      Quite frequently. Hep B, Hep C, Hep E, CMV, HIV, EBV, varicella-zoster, HSV, HPV frequently coexist with each other and with other viral infections, for instance.

      “HP like it or not it is more in line with how people, who have life long immunity, got viruses historically, either orally or inhaled.”
      There are many other routes for acquiring virus infections. I don’t follow your reasoning here at all. It seems to be in line with magical thinking.

      “Science – who should I trust”
      You could start with your family doctor.

      “the healthiest with the fewest visits are his completely unvaccinated patients”
      The uptake of medical services is not a good measure of health. Parents who do not take their children to be vaccinated are less likely to take up other health checks and screening visits, and less likely to pick up on health problems generally.

      “I’m a CHRISTian and commanded to test everything”
      Testing everything rather than accepting dogma is the first prerequisite of scientific enquiry.

      “Studies are not done to test multiple vaccines by different manufacturers, and this is a guess, because adverse results would be blamed on the other guy”
      Yes they are. Don’t guess: check your facts.

      “an age where information has increased as prophesied in the Old Testament
      I don’t understand what you mean by this, though I would be interested if you could give the reference.

      “Just like when doctors began washing their hands outcomes for patients improved, it was the improvements in clean water, better sewage and plumbing that reduced infectious diseases that vaccines got the credit for.”
      Ignaz Semmelweiss started the practice of hand-washing based on careful observation of outcomes in a maternity unit. He was rewarded by incarceration in an insane asylum and an early death, probably from being beaten up. However, hand-washing can prevent the transmission of a great many infections (including very common problems such as staphylococcal food poisoning, flu and the common cold) and there is a lot of room for improvement here.

      It is certainly true that improved sanitation (together with an understanding of microbial causes of disease) has had a major impact on public health, and this is generally credited appropriately. On the other hand it has much less of a role to play in the case of measles, hepatitis B, smallpox and many others.

      “same dismal autism rate as stated by the very same CDC, I believe currently 1 in 50”
      Again I’m not clear what you are saying here. There is no evidence whatsoever of a connection between autism and vaccination, and the apparent increase is due to improved diagnosis.

      “Immune” from lawsuits.
      Short window for lawsuits.
      Sealed documents.
      Loophole in sueing them closed by SCOTUS by saying vaccines are unavoidably unsafe.
      CDC has a monetary stake in many vaccines so there is s conflict of interest.

      It is rather hard for me to comment on all that, which only applies to one country, but not one I am particularly familiar with.

      “I will offer an analogy.”
      I find it rather hard to construe the paragraph that follows as being an analogy. Are you saying that the reduction in some infections as a result of vaccination is analagous to the reduction of others as a result of sanitation?

      “men lie about history”
      Very true. One big advantage of science over the humanities is that individual opinions count for nothing – the only arbiter of truth is Nature.

      • Thank you Dr Julian for your response. Be quick to listen slow to speak…James 1:19 Saw you post a few days ago and paused to think and question. Yes you could get a mosquito bite, cut your foot on dirty ground, drink infected water and have someone sneeze in your face but in the vast majority of cases the news, CDC and WHO highlight a single virus. I found a “top 10” list of worldwide virus outbreaks but none were multiple viruses. I asked some people ages 47 to 85 (not very scientific I know) but 1 in 12 said they heard one time of a person who was host to more than one virus and none given true informed consent about all the components of the vaccines they or their kids were administered. The vast, vast majority are single viruses otherwise that would be a great selling point for the pharmaceutical companies and the CDC, or highly unlikely.

        These issues will all be resolved by GOD’s justice with the evil punished. More important is your salvation and anyone who reads posts like this one. Logically dogma is “completely” appropriate if it’s true and only then. GOD will make that clear as well. The problem: GOD is true and every man a liar.

        the only arbiter of truth is Nature.
        The only arbiter of truth is GOD. Men study HIS creation, nature, and only some come close to the truth and others outright lie and there are those in between. The rest struggle with who is truly credible, with respect to medicine and science I fit in this group. You may have guessed I filter everything through the Bible…. By no means! Let God be true though every one were a liar, as it is written, “That you may be justified in your words, and prevail when you are judged.” (Romans 3:4, ESV) The word of GOD calls me to sober thinking nothing magical here believe it or not.

        “Witch” doctors, pun intended, should I listen to:
        The Dr that diagnosed my wife’s lupus offered us conventional medical intervention, which her sister also with lupus has followed, the result being always sick, in pain and overweight after 10 years of conventional medicine, which we declined to pursue natural alternatives. She then told us my wife she could no longer be her patient. I understand that is not how doctors are supposed to “practice” medicine, oh well. We would have signed a waiver so she could at least monitor my wife. With no medical supervision but some direction from a Dr we met briefly, after a year and a few months we found that Dr again who was not quick to pull out the Rx pad and started her own practice. She checked my wife and in her words her lupus came back zero. As a side note every time my sisters-in-law visits and eats as we do taking the natural remedies my wife does before she leaves she is pain free and puts her cane aside – how magical.
        Or the Medicaid Dr who on our first visit with our granddaughter was ready to put her on a schedule to get her caught up on vaccinations, who at birth only got vitamin K. We declined and heard an echo, she can’t be my patient… you know the rest. A gift from GOD, 15 months, sick 3 times, taken care of naturally by us, her new Dr, one who does vaccinate and gets it, said we did the right things to get her well.
        A doc friend of mine who accepts that as part of the medical community he is required to be vaccinated shared with me that they won’t know for years what the vaccine he just got will do. Do I trust him, not my regular physician, or you or someone else. He said this to me as a friend so I believe him. Would he say the same to his patients? Wish I had thought to ask that years ago back in NY. Or the Dr…that’s enough. There is no science for each of those episodes and more where a Dr shot the medical community in the foot.

        While I accept dogma from GOD, if you mean man, I agree I am not quick to accept their dogma. Vaccine injury does not ask your level of education, income or any other demographic. So many in the anti-vax movement are from a variety of demographics. That being said those who do not vax tend to be more educated and of higher income brackets who test first then decide about the need for medical attention. You statement about the uptake of medical services could be right but also could be wrong! You would need more information to support your statement and not blanket non-vaxers with information you could not possibly know. An example of how our testing methods fall short.

        Information / reference – Daniel 12 please read in context. Applicable to all information because all truth belongs to GOD.

        Because there is no temptation except that which is common to man 1 Cor 10:13 and The heart is deceitful above all things, and desperately wicked: who can know it? Jer 17:9. In other words if there were a person completely honest in a particular field, do you think that person could assert with confidence that every person in his field was as he claims to be – no, not at all. Therefore anything in creation that has a human hand on it also has hearts with varying degrees of integrity and evil as GOD describes. No one can claim any advantage because letters or titles on a name do not , never has and never will confer integrity with it.

        I am sure we all could say more but my post is not intended to be a bible. There is a bible verse for that as well which states: When words are many, sin is unavoidable, but he who restrains his lips is wise. I appreciate the fact that you at least made me pause, ask questions, (as I stated test) and think though my personal experiences and learning have me not agreeing with you.

        • @Joe

          From your comment I’m guessing that the god you think is the source of all things true is the one worshipped by Christians. Please will you tell us how you came to choose this particular god? Did you first also consider the gods of Islam and Judaism (they’re supposed to be the same as the Christian god but they offer quite different versions of ‘truth’). Did you consider the gods of the Hindu and Sikh religions or the views of god expressed in Jainism and Buddhism.

          All of these religions believe they have the truth, yet the truths all seem to differ. So please tell us what criteria you used to come down in favour of the Christian god. I’m sure if you’re using your god as a debating point you’ll have more to offer than “it’s what I was brought up to believe”.

          • Dear Professor Frank Odds

            There is only ONE God; all around you and inside you, for goodness sake!

            Cheers

          • if you say so!
            but why then did mankind fight each other incessantly since we began to worship, because we did not appreciate those who were praying to another god than we did?

          • “did not appreciate those who were praying to another god”
            Or indeed praying to the same god but in a different way (Catholics vs. Church of England, Catholics vs. Hugenots, Calvinists vs. Lutherans, Arians vs. Athanasians, Sunni vs. Shiite…).

          • CORRECT!

          • Hi Frank,

            Thx for reading my post. I’m no theologian. Just a born again believer walking in love and obedience to my GOD endeavoring to be prepared to give an answer for the hope that is within me with gentleness and respect. Yes I am a born again CHRISTian called to know, serve and love my GOD and test everything, the two are not mutually exclusive.

            While I am asked to have faith like a child, innocent and trusting, GOD, the CHRISTian GOD, doesn’t ask me to park my brain outside. For example I believe that if my GOD did not exist there is no amount of futile physical, mental or emotional exertion I can do that can create HIM, not to mention at that point HE would be a created god. On the other hand no amount of unbelief from all of mankind throughout all our earthly history can force HIM out of or to never have existed. Even men of science and all mankind in general are left with two options: matter is eternal, we came from matter and created a non existent god or GOD is eternal, created man and all things and man desires to know HIM or act as if HE doesn’t exist. Maybe I’m just a very rational crazy person.

            I am hispanic and could easily question why I should follow a dead Jewish guy who I am a few 1000 years removed from. As I tell everyone the only reason to believe anything is because it’s true. I was brought up Catholic but not by parents strong in the faith, my mom far more believing than my dad. As I grew I questioned more even playing Devil’s advocate opposite CHRISTians who had no or poorly articulated their answers. Near the end of my time as a catholic I would just go to church stare at the image of JESUS on the cross in church as I listened to the priest’s message and wonder.

            I met a former Pentecostal who shared some amazing, interesting and strange experiences with me who was going to a Catholic Church. Interesting how you can start with the truth and make up the rest which is what we believe the Catholic and Pentecostal denominations have done. We married and long story short found ourselves in an independent church where in one sermon the pastor said “don’t take it from me, read or for yourself.” I’ve read my entire bible and come away believing it’s true, convinced! Or you could believe the natural progression of science where now some like GOD denying Lawrence Krauss explain a universe out of nothing: https://youtu.be/46sKeycH3bE
            Please carefully listen to his explanation, test. I have one closer to the truth but won’t share it right now that as a thinking person I did not get or hear from another teacher.

            We all have the same evidence, even in the vaccine/HP debate but when we argue do we argue from all points in other words the truth.

            I did not see reply buttons for Dr Julian, Edward or Gregg so I will answer here. Hope you read their responses.

            Gregg: If you were being sarcastic I get it but if not the HOLY SPIRIT only resides in believers but GOD has given everyone a conscience.

            Edzard and Dr Julian: If it is as atheists say then you have your answer: mankind or manselfish following the imaginations of his mind, idols created in the image of man. If GOD exists though I believe some believers took part in these wars, you have two possible answers. 1-see above. It is logically possible for there to be a GOD and unholy men do as above while a holy GOD is keeping account of those who truly follow HIM as well as those who don’t. 2-the worst possible answer for unbelievers that GOD called men to war against unbelievers. The reason unbelievers reject this is because individuals can’t conceive of anyone holier than themselves and can’t fathom standing before a holy GOD who knows the secrets of the heart. It is a fearful thing to fall into the hands of the living GOD. Contemplate that-honoring father and mother while no: murder, adultery, stealing, lying, coveting etc. Not that I believe that happened after CHRIST ascended where the vast majority of these conflicts took place. JESUS warmed Peter, those who live by the sword die by it.

            In case you wonder if I really test listen to Krauss and see if my assessment is correct. He redefines some terms. How convenient. He says something about particles that is conflicting. If he is correct about jumping in and out of existence then they have a power we know nothing about but I am sure he can define. Are those particles time traveling or realm traveling? In the full interview if I used the wrong link he says there is no evidence for GOD in creation. If he was looking how would he know if he found it if everything is scientifically explained. Think about it!

          • Forgot this at the risk of another analogy: does the vaccine GOD exist regardless of men on opposite sides of the argument. Of course they are independent of each other.

        • Hi Joe,

          Thanks for the response. We obviously have a fundamentally different view of the world we live in. I don’t see the hand of any loving, interventionist god anywhere. From your comment you see both nature and God as the only arbiters of ‘truth’: however, nowhere do you define exactly what you mean by God (or, for that matter, ‘truth’: you use the word in a different sense from meaning ‘objectively determined fact’). Without precise definitions, anything is entirely beyond discussion. (My ‘loving, interventionist’ adjectives begin to define what most Christians seem to think about their god but it’s still a long way from anything precise enough to debate rationally.)

          I’m not surprised that you find Lawrence Krauss difficult or impossible to believe. Like most present-day physics, his explanation of a universe (or cosmos) originating from nothing flies in the face of everyday human experience. One useful starting point is to recognize Krauss’s very precise (physical) definition of ‘nothing’.

          You say “We all have the same evidence, even in the vaccine/HP debate but when we argue do we argue from all points in other words the truth.” I find this somewhat weird, and certainly don’t accept the first (comprehensible) part. There’s a world of difference between verifiable evidence and supposition; opponents of vaccination seem to work entirely with the latter.

          I’d like to suggest you read Steven Novella’s The skeptics’ guide to the universe, which is a very good account of how easily we humans deceive ourselves, but I fear you’re too far gone in the world you’ve created for your beliefs to be shaken up by any suggestion of self-delusion. So I’ll just close by saying “good luck to you, Joe”.

          • Hi Frank,

            Thank you for responding. Most people believe all religions are fundamentally the same and superficially different but the opposite is true. Though I was catholic I now consider myself CHRISTian. In the same way men disagree about just about everything, vaccines vs HP for example, the same is true for world-views. JESUS said make disciples not denominations, the results of both men’s disagreements and at worst desiring to be in a sense a god, btw the error of men.

            We stand in awe of nature for all we say it provides yet fear its destructive power. We talk about good and bad bacteria but both are required in the proper balance in our bodies. There are other examples but our description of GOD is the most important. Statements or questions about HIS character are always one sided making GOD an idol, of our imagination, a straw man to debunk. The GOD I serve is not only loving but holy, just and even wrathful.

            The primary reason for suffering is sin. Which sins should GOD prohibit, only the big sins which are evident in the question of global sufferings or the innocent victim or all sins including the “white lie.” If HE dealt with every sin because HE is holy, sinless, HE would also deal with every individual, me included. Justice is good but perfect justice will be decided by GOD. We however want justice here and sometimes we get it. Unfortunately the vaccine manufacturers are the only entity immune from it, man’s decision. So what about suffering imposed by the pharmaceutical giants?

            By GOD I mean the CHRISTian GOD, all knowing and powerful as well as other attributes. Why? This goes to the meaning of what is evidence. By the way here is Krauss saying science can redefine words: https://youtu.be/SK35bv3M7yg. I was understanding him just fine. Do you think particles popping in and out of existence, his description, would be proof of GOD for him, not on your life. With respect to nature for example it’s either evolution or creation, we all have the same evidence interpreted differently, incorrectly or lied about which can happen on both sides. Yes I am supposed to test CHRISTians also. I believe but can’t prove GOD’s order of creation was intentional to not fit with evolution. GOD’s word tells us the wisdom of the world is as foolishness to GOD. A truth claim to be accepted or rejected. I will be talking more about truth when I respond to Edzard. What of dating methods that are thrown out if they show a young earth because you need an old earth for evolution? Btw all dating methods are handicapped by assumptions.

            Faith is perfectly rational. Unfortunately when science is GOD and all explanations can only be scientific a Krauss, and all who believe that way, can say they can’t prove there is no GOD as Krauss has stated but don’t mean it. For then rationally they should say GOD is a plausible explanation until proven otherwise. Yes I listen carefully to him. Did you pause when you wrote flies in the face of everyday human experience since that is what CHRISTians believe about GOD and HIS miracles: creation out of nothing (truly nothing which in a debate with Dinesh D’Souza, Krauss says truly nothing), parting the Red Sea, conception without intimacy, resurrecting a body etc.

            What I mean about all the evidence is the good, bad and ugly. The idea behind vaccines sounds reasonable. If I use Krauss’s truth claim, nothing is 100% in science then I can’t claim they never work and the vaccine pushers can’t say they do either. But who gets to define work. Have you ever asked yourself how do they determine the efficacy of a vaccine? They would have to know every person who has been vaccinated, whether or not they’ve been exposed to the wild strain to test and verify if the vaccine strain protected them. Impossible, so they need to guess and it will always be in their favor. Or what of the people who catch the vaccine strain through shedding, I am certain you’ve heard of that, is that reported accurately? Too long so finally there is: immunity for manufacturers, vaccine court, sealed cases, most cases thrown out, the inept VAERS with only 1% of reporting because vaccines supposedly don’t cause injury. If this guy is lying they should sue him and put him in jail, https://youtu.be/ApH3y9aXiMc. Hope you listen to the whole video. Suffice to say if you or anyone could prove similar for HP they would be even but that smoking gun isn’t there. Vaccines are found wanting for much and destroy lives in other ways also. This is what I mean by all the evidence. There will be more in my post to Edzard. Hope you consider these things.

          • @“Joe”
            Doesn’t it say somewhere in the code of christian religious ethics (the bible), that you are not allowed to tell lies? Ignorantly propagating dangerous antivaccine untruths is not going to be taken lightly at the gates of heaven!

          • @Joe

            Since this blog is concerned with pseudo-medicine and not religion, I’m not going to react to most of your comment, even though the border between the two is often very blurry.

            But on the subject of vaccination, you said: “Have you ever asked yourself how do they determine the efficacy of a vaccine? They would have to know every person who has been vaccinated, whether or not they’ve been exposed to the wild strain to test and verify if the vaccine strain protected them. Impossible, so they need to guess and it will always be in their favor.”

            That’s exactly what happens, Joe. In the UK. conditions like measles, polio, rubella and mumps are notifiable diseases which means that, by law, doctors have to notify a (defined) authority of every case that occurs. In the USA, the CDC or State Health Board is the place where notifiable diseases are reported. Until 2000, when measles was almost eradicated in the USA, measles was a legally notifiable disease across the USA, and it still is, in some states. (I’m not going to take the time to look up the other vaccine-related diseases in the USA: many or most have been notifiable in the past: it’s only the success of the vaccination programs that took them off the list.

            So we know (in the UK and many other countries) all the cases of notifiable diseases. We know exactly what proportion of infants have received vaccines against these diseases. And we can see the effects very clearly. So I suggest you take a look at this and stop pushing the total nonsense you’re pushing against vaccination, because you’re contributing to killing people, Joe and God says very clearly in the bible that you shouldn’t be doing that.

          • I hope you don’t thin you are to only one to receive serious threats;
            some of us still do have the integrity to use their name.

  • @Joe: thank you for your post! It is amazing and such a blessing to know that I’m not the only one here that the Lord, Jesus has chosen to proselytize the masses….I am of course the most humble, most important and spiritually advanced but having troops like you to call on is important! I, like you, recognize my overwhelming superiority to the majority of lessers the Lord has inexplicably filled the planet with. I’m sure we’ll meet one day in heaven. Well I know I’ll be there, I’m just guessing about you…but I can put in a good word if you’d like, I have pull.

    • Hi Michael,

      I hope and pray we both find ourselves in GOD’s presence but please take care of the posts you write. Please reread your post in light of (please read in context) Philippians 2:3-7 and Romans 14:4. Fight the good fight!

  • @Joe: the Old Testament is history become myth….the New Testament is myth become history.
    God is and will forever be just the voice in your head, irrespective of your arrogance, self-righteousness and powers of self-delusion. You should consider looking into humility-training, you’ll begin to recognize you’re not all that special and the grand designer really has no particular interest in whether you live or die. Just like the rest of us, and just as it should be.

    • Hi Michael,

      Thank you for your response. I gave you the benefit of the doubt because followers of CHRIST are not all in the same place but thank you for the revelation that my first impression was correct. I said nothing arrogant by asking someone I thought was CHRISTian to show more humility in their post, it’s biblical. You also seem to describe the post you wrote that I responded to. I also stand behind my posts since I don’t need to know it all but enough, especially what is public record on the lies of big pharma and the vaccine manufacturers. Hope you consider these things.

  • how do they determine the efficacy of a vaccine? They would have to know every person who has been vaccinated

    I also stand behind my posts since I don’t need to know it all but enough, especially what is public record on the lies of big pharma and the vaccine manufacturers

    You are explicitly holding health professionals to a higher standard of evidence than yourself and then you contradict their advice. What are we supposed to make of that?

  • Yes they are to be held to a higher standard. They are saying a product is safe and effective that they needed immunity from lawsuits for yet that has killed and injured thousands. I have no such products. Any other product would have been allowed to fail out of the market if it were a car, cell phone, food item even pet food.

    I worked for a pet food distributor that was required to recall over a million $ in pet food due to ecoli but vaccines kill people and they have a blanket called safe and effective. How backwards is that? Please keep in mind I did not cause all the news that is a matter of public record. All they did was keep saying they’re safe when they knew otherwise. Btw that was a very small part of a national recall. I knew enough about that also but not everything. I was the accountant required to track the product, refunds to customers and reimbursement from the manufacturer. Why did they not get away with it but vaccine manufacturers just keep going to the bank. Not to mention the CDC pushing vaccines they have $hares in. Quite the conflict of interest.

    • “but vaccines kill people”
      “the CDC pushing vaccines they have $hares in”

      Saying something you believe to be true does not make it true, Joe

      At the top of the page, it says “Please remember: if you make a claim in a comment, support it with evidence”

      I see no evidence and that which is claimed without evidence can be dismissed without evidence.

    • Yes they are to be held to a higher standard.

      A higher standard of EVIDENCE. Can’t you read?

Leave a Reply to Zanda Sebastian Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

If you want to be able to edit your comment for five minutes after you first submit it, you will need to tick the box: “Save my name, email, and website in this browser for the next time I comment.”
Recent Comments

Note that comments can be edited for up to five minutes after they are first submitted but you must tick the box: “Save my name, email, and website in this browser for the next time I comment.”

The most recent comments from all posts can be seen here.

Archives
Categories